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Abstract
Dissolution studies provide valuable and critical drug release information (in vitro) that are
important for quality control drug development. Using in-situ FT-IR spectroscopy methods has
been developed for analyzing and monitoring dissolutions of pharmaceutical APIs. The accuracy
of this technique was found to be ± 3% relative to HPLC and UV/Vis Spectroscopy. A dynamic
analysis of the dissolution and subsequent hydrolysis of aspirin has been determined by in-situ FTIR. This technique allows real-time analysis of the behavior of aspirin under simulated
physiological conditions (pH 1.2, 4.5, 6.8) as aspirin (1205 cm-1) and salicylic acid (1388 cm-1)
are detected as separate and distinct peaks in the in-situ FT-IR.
For this study, 325 mg Bayer aspirin tablet was used. The data shows dissolution of aspirin with
the hydrolysis profile and the formation of salicylic acid. Comparison of the dissolution behavior
of generic brands of aspirin has been performed. The formulations contain the same amount of
drug substance as present in Bayer aspirin. Dissolution and hydrolysis of enteric coated aspirin
tablets has been performed, and compared with the Bayer aspirin tablets. The dissolution was
carried out as per the USP procedure.
This technique indicates a future potential for real-time studies of dissolution and hydrolysis of
other prodrugs such as Loratadine. The in-situ FT-IR system is extremely capable of measuring
low concentrations (0.03 mg/ml) and for distinguishing separate components of a multiple
component systems without requiring manual sampling. Specifically, the unique fingerprint region
of the in-situ FT-IR spectra provides detailed information about the release profile of the drug.
One more demonstration of the in-situ FT-IR novel technique is the dissolution study of Loratadine

v

(hydrolysis of Loratadine), a pro-drug that has a tendency to hydrolyze to an active compound
desloratadine.
In addition, research on the acetaminophen dissolution observed on extra strength Tylenol and on
Tylenol Arthritis has been validated by UV/Vis spectroscopy and HPLC. In this study the nonlinear behavior of Beer-Lamberts’s law was observed. The hypothesis has been established that
the acetaminophen forms dimer at higher concentrations. The investigation was carried out by
NMR and FTIR Spectroscopy and by measuring colligative properties such as vapor pressure
osmometer and freezing point depression.
In-situ FT-IR spectroscopy is a novel technique used for monitoring the dissolution testing. The
fingerprint region of the in-situ FT-IR has great potential for studying dissolution kinetics as well
as hydrolysis kinetics for aspirin. A separate peak for aspirin as well as salicylic acid has been
observed. This technique has excellent potential for the dissolution studies of tablets without
disturbing the dissolution media.
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CHAPTER 1
INTRODUCTION

1.1

Introduction

Dissolution of solids has been studied for many decades and applied to many industrial fields for
various chemical or physical applications, for example, food and pharmaceutical products.
Dissolution is the process by which a solid substance enters the solvent phase yielding a solution.
[1] In the past few years, the importance of dissolution testing has increased substantially, as seen
by the high level of regulations imposed on the pharmaceutical industry by various health agencies
around the world. Dissolution testing is critical for measuring the performance of a pharmaceutical
formulation. For a solid dosage from, it will be disintegrated into small granules then dissolution
process of the granules can be studied and its outcomes such as solubility can be obtained.
Dissolution testing plays several important roles in the pharmaceutical industry. First, the
dissolution test is a quality control tool that measures the change in stability of the formulation.
Some of the relevant changes that dissolution testing is able to detect include changes caused by
temperature, humidity, and photosensitivity. Second, the dissolution testing is also important for
formulation development. During development of a drug product, the formulators use dissolution
testing to distinguish between different variations of the drug product. The physical characteristics
of particles applied in dissolution studies are normally pointed as its objective properties. The
physical properties of particles are related to its size, shape, surface and structure. In the
pharmaceutical industry, it is important to develop with several variations of the drug product since
these are needed to access the drug’s performance in clinical trials. From the clinical trials, the
1

efficacy of the variants is distinguished and obtained. Third, once in vivo (clinical trials) data has
been established for the drug product, a correlation between in vivo (human blood data)/ in vitro
(lab dissolution results) is attempted. [2] [3] Fourth, dissolution testing is used for the development
of the quality control specifications for the manufacturing process, such as compression and
binding agents in tablets and other parameters for other dosage forms. [4] With this, dissolution
plays a very important role for measuring the stability of the investigational product. In the
manufacturing industry, another application of dissolution testing is to assess the batch-to-batch
consistency preferably in solid dosage forms. Finally, the Food and Drug Administration (FDA)
requires dissolution testing in regulatory filings for all oral dosage forms and many other dosage
forms as well.
Dissolution is the process by which a solid dosage form enters in the dissolution media to yield a
solution. It is simply a process by which a solid dosage form dissolves. It is controlled by the
affinity between the molecules comprising the solid substance and the solvent. Moreover, the
dissolution rate plays an important role in the understanding of dissolution chemistry. The
dissolution rate is defined as the amount of drug substance that goes into solution per unit time
under standardized conditions of liquid/solid interface, temperature and solvent composition.
Dissolution testing can be performed using different types of testing apparatus for pharmaceutical
dosage forms. Even though there is increased research interest in this area, the techniques used for
studying dissolution rates remain constant. In fact, there are only a few instruments used to analyze
and understand the dissolution rates of drugs. This chapter discusses the current techniques used
for dissolution testing. Additionally, a detailed literature review into the use of in-situ FT-IR
spectroscopy in general and as a dissolution technique has been made and is discussed in this
chapter. [5]
2

1.2

Dissolution Models and Theories

In the dissolution research, Higuchi provided fundamental contributions to the development of
dissolution theory. [6] According to Higuchi’s research, there are three basic models used alone or
in combination to describe the dissolution process and mechanisms. These three models are;
diffusion layer, interfacial barrier and Danckwerts.

The diffusion layer model was simply used for a crystal solid to describe the dissolution process
in the pure solvent without any reactive actions. This model was once expressed by Nernst. [7]
According to the diffusion layer model as shown in Figure 1, it is assumed that there is a saturated
layer of solvent Cs around the solid surface and equilibrium conditions occur on the surface. Then
the dissolution process is driven by the diffusion movement of molecules in the diffusion layer, δ
cm in thickness. Therefore the dissolution process can be expressed such that the first step of solid
forming an interface in the solvent is very rapid. This leads to the formation of a saturated stagnant
layer around the surface. Then slow diffusion occurs from the surface into the bulk solution
through the diffusion layer. The rate of dissolution is entirely based on the diffusion of the solid
molecule from the diffusion layer to bulk liquid.

3

Figure 1: The diffusion layer model
(All figures in this dissertation were created by Vrushali M.Bhawtankar)
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The interfacial barrier model assumes that there is a high activation energy to promote the
interfacial transport process. [8] According to this model as shown in Figure 2, a free energy barrier
surmounts before the solid can dissolve. The surface of the solid is continually exposed to the
solvent and equilibrium is assumed at the solute-solvent interface Cs. The solute then diffuses from
free energy barrier and is carried into the solvent under the agitation. This leads to the formation
of a saturated stagnant layer around the surface. Then slow diffusion occurs from the surface into
the bulk solution through the diffusion layer. Therefore there is no layer around the surface and
the surface is continually replaced by the solvent medium.

The Danckwerts model assumes that the macroscopic packets of solvent reach the solute-solvent
interface first by eddy diffusion in some random fashion [9] as explained in Figure 3. At the
interface, the packet is able to absorb solute according to the laws of diffusion and then replaced
by new packets. This process continually occurs and the surface is continually replaced by the new
packets of solvent. Therefore the surface renewal process can be related to the solute transport
process.

These three models explain the mechanism of the drug dissolution testing, where solid drug reacts
with the fluid of dissolution medium. This reaction takes place at the solid-liquid interface.
Therefore dissolution kinetics are dependent on three things-the flow rate of the dissolution
medium towards the solid-liquid interface, the reaction rate at the interface and the diffusion of the
dissolved drug molecules from the interface towards a bulk solution. The most commonly used
model is diffusion layer model.

5

Figure 2: The interfacial barrier model

6

Figure 3: The Danckwert's model
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1.3

Mathematical Models of Dissolution

The in vitro dissolution has been recognized as an important testing in the drug development. There
are several mathematical and kinetic models for dissolution testing are greatly developed and
explained. These models describe drug dissolution from immediate and sustained release dosage
forms. There are several models represents the drug dissolution profile, which is a function of
time-related to the amount of drug released from the pharmaceutical dosage form. [10] This section
covers a brief information about each model with the final derived equation.

There are many fundamental mathematical models based on the Noyes-Whitney equation and on
Nernst-Brunner film theory on dissolution kinetics which can be expressed as statistical methods.
These include the exploratory data analysis method, repeated measures design and multivariate
approach. Model dependent methods including the zero-order model, first-order model, Higuchi
model, Hixson-Crowell model, Baker-Lonsdale model, Korsmeyer-Peppas model and Weibull
model have been developed. Model independent methods including difference factor and
similarity factor also have been used.
The first equation for dissolution kinetics was described by Noyes and Whitney in 1897 with the
equation. [11]

𝑑𝑀
= 𝑘𝑆( 𝐶𝑠 − 𝐶𝑡 )
𝑑𝑡

(1)

Where M is the is the dissolved mass, t is the dissolution time, S is the surface area of particles,
CS is the equilibrium solubility at the temperature, Ct is the concentration in solution at the time
and k is the dissolution rate constant.

8

This Noyes-Whitney law was developed from observing the dissolution of two different materials
dissolving in water. With this equation, the dissolution could be assumed to be driven by the
difference between the concentrations at the particle surface, which can be regarded as the
equilibrium solubility with the concentration in the bulk. Therefore the dissolution process was
controlled by the mass transfer from the surface of the particle to bulk.
Then, the dissolution mathematical model was greatly developed by Brunner and Nernst. In their
studies, a relationship between diffusion coefficient and the concentration in bulk was explained.
The equation to describe this theory is expressed by Nernst and Brunner as

𝑘=

𝐷𝑆
𝑣ℎ

(2)

Where D is the diffusion coefficient, h is the diffusion layer thickness,  is the volume of solution,
S is the surface area of particles and k is constant. With this model, Nernst and Brunner stated that
the dissolution process could be proposed in two steps. They assumed that the fluid in the diffusion
layer was stagnant. Furthermore, this theory also assumed that the dissolution process at the
surface of the particle is much faster than the mass transfer process and a linear concentration
gradient happens in the particle surface layer. However, this ideal condition assumption may never
occur because the surface area of the particle changes permanently with the dissolution process.

Exploratory data analysis
This method is used to understand and compare the dissolution data with a controlled dissolution
process. [12] The comparison can be achieved with dissolution data in graphical and numerical
methods. The dissolution data can be plotted for every formulation with one or two error bars at
each dissolution time point. Therefore the dissolution data can be summarized numerically and the
differences between every dissolution data profile can be compared at each dissolution time point.
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Multivariate approach
The multivariate analysis of variance (MANOVA) is a statistical method, based on the repeated
measurements designs where the percent dissolved material is depended with the repeated factor
of time. With the repeated measurements, the factors are measured repeatedly with more than two
levels. [13] The data were collected with repeated measurements over time on the same
experimental instrument. These are compound symmetry assumptions and the assumptions of
spherocity, it refers to the condition where the variances of the differences between all possible
pairs of within subject conditions are equal. Because of these assumptions, MANOVA approach
to repeated measures has gained popularity in recent years.

Zero-order model
The zero-order model assumes that dissolution is independent of the concentration in bulk, and is
only changing with dissolution time. In this way, the application of this model is limited with the
only consideration of dissolution proportional to time. This model states that dissolution from
particle will not disaggregate and the process is slow. [14] This model is expressed as

𝑄𝑡 = 𝑄0 + 𝑘0 𝑡

(3)

where Qt is the amount of particles that has dissolved at time t, Q0 is the initial amount of particle
and k0 is the zero-order dissolution constant.

First-order model
This method is usually used to describe the absorption or elimination of solid particles. [15]
However, the mechanism of dissolution process with this model is difficult to be conceptualized
from a theoretical context, as after saturation point with the first-order dissolution rate shifts to
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zero order. Because of this scenario, it is also called mixed-order kinetics. The first order kinetics
can be represented as follows, where dC is the change in concentration, dt is the change in time, C
is the concentration and kf is the first-order dissolution rate constant.

−

𝑑𝐶
= 𝑘𝑓 𝐶
𝑑𝑡

(4)

Higuchi model
This model was firstly expressed by Higuchi to describe drug release from a matrix system. The
assumption of this model can be described that the initial concentration should be higher than
solubility, and the diffusion occurs only in one dimension, the drug particles are much smaller than
diffusion layer thickness. [16] The model can be expressed as

𝑄 = 𝐴√𝐷(2𝐶0 − 𝐶𝑠 )𝐶𝑠 𝑡

(5)

where Q is amount of dissolved particles in area A at time t, C0 is the initial concentration, CS is
the solubility of particles and D is the diffusion coefficient of particle molecules. The common
application of this equation is the simplified equation where kH is the Higuchi dissolution rate
constant.

𝑄 = 𝑘𝐻 𝑡 1/2

(6)

The application of the Higuchi model is for the drug release from the dispersed matrices to particles
of general shape using the pseudo-steady-state approximation of Higuchi. [17]

Hixson-Crowell model
This mathematical model was first expressed by Hixson and Crowell as the particle regular area is
proportional to the cube root of the volume. [18] The equation can be described as
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1/3

𝑊0

1/3

− 𝑊𝑡

= 𝑘ℎ 𝑡

(7)

where W0 is the initial concentration of drug in pharmaceutical dosage from, Wt is the remaining
concentration of drug in pharmaceutical dosage from at time t and kh is the Hixson-Crowell
dissolution rate constant. This model assumes that the surface of the tablet is allowed to change
with time and its geometrical shape diminished proportionally with time. Hixson and Crowell
expressed that the dissolution rate was controlled by the particles dissolution rate rather than the
diffusion speed through the diffusion layer.
Korsmeyer-Peppas model
This model was expressed by Korsmeyer, in 1983 as a simple relationship to describe the drug
dissolution from a polymeric system. [19]

𝑀𝑡
= 𝑘𝑡 𝑛
𝑀∞

(8)

Where Mt/M is the ratio of dissolved drug at time t, k is the dissolution rate constant and n is the
exponent. It is noticed that the value of n is used to define different dissolution types for
cylindrically shaped matrices.

The review of the kinetic modeling on the drug release show that these models have been
established to describe the relationship between drug dissolution and geometry on the drug release
patterns mathematically. The drug transport inside pharmaceutical systems involve multiple steps
provoked by different physical and chemical phenomenon making it difficult to formulate a
mathematical model describing it in the correct way. The release models with the major application
and the commonly used to study drug release phenomenon are the Higuchi model, zero order
model, first order model and Korsmeyer-Peppas model.
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1.4

USP Dissolution Information

In the history of dissolution the results reveled in late 1800’s to the mid-1900’s, the first official
dissolution testing method appeared in United States of Pharmacopeia XVIII in 1970. The United
States Pharmacopeia or USP is a non-government, official public standards–setting authority for
prescription and over-the-counter medicines and other healthcare products manufactured or sold
in the United States. [20] The USP also sets widely recognized standards for food ingredients and
dietary supplements. The USP sets standards for the quality, purity, strength, and consistency of
these products which are critical to the public health. Increased interest in dissolution regulations
continued to grow well into the 1970’s.

In 1978 the Food and Drug Administration (FDA) published the document entitled, “Guidelines
for Dissolution Testing.” [21] The intention behind this publication was to harmonize and
streamline the systems and processes of different laboratories. This was due to the fact that
dissolution results were observed to have high variability. There are minor changes in the
equipment parameters which causes higher variability. The FDA realized that more controls on
the tolerances of the dissolution equipment were needed so that results would be more
reproducible. Additionally, the FDA along with USP introduced the idea of calibrator tablets.

In 1978 the USP launched three calibrator tablets; prednisone, salicylic Acid and nitrofurantoin.
These calibrator tablets were used during the calibration of the instrument to validate the
dissolution testing system. The calibrator tablets have known specification limits and the
calibrations of the instruments have to be within those limits. To have an appreciation of the
13

complexity of the dissolution system and equipment parameters, an overview of the technology
will be given in the next section.
In 1995, the USP assigned unique numbers to the different dissolution apparatus that were
available to the scientific community. All dissolution testing apparatus are listed in Table 1. There
are seven different types of dissolution equipment that are available to the dissolution chemist. The
most widely used dissolution apparatus in the pharmaceutical industry are apparatus I, II and IV.
The use of apparatus IV has been developed more importance in recent years.

Apparatus 1 and 2 are most widely used in the pharmaceutical industry. As shown in Table 1,
Apparatus 1 uses baskets while Apparatus 2 uses paddles. Figure 4, shown below, is a schematic
and brief illustration of these two apparatuses and more precise dissolution testing vessels. The
apparatuses are comprised of a covered vessel which is cylindrical with hemispherical bottom with
capacity of minimal 1 liter, a metallic drive shaft which rotates smoothly that could affect the
results, a motor to spin the shaft, a cylindrical basket (Apparatus 1) or a paddle (Apparatus 2)
which are explained in detail in figure 5 and 6 respectively and dissolution medium.

The dissolution testing apparatus comprised a water bath or heated jacket capable of maintaining
the temperature of the vessels at 37°C ± 0.5°C. The dissolution testing apparatus is connected to
the auto sampler and if not then need to collect aliquots manually at the particular time point.
Although the figure below appears simple in design, there are strict regulations for the
specifications of each component of the apparatus and tolerances for each component are specified
by USP General Chapter Dissolution <711>. [22]
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Table 1: List of dissolution apparatus as per USP [20]

APPARATUS

NAME

DRUG PRODUCT

Apparatus 1

Rotating basket

Tablets, Capsules

Apparatus 2

Paddle

Tablets, capsules, modified drug products

Apparatus 3

Reciprocating cylinder Extended-release drug products, Beads

Apparatus 4

Flow through cell

Drug products containing low-water-soluble drug

Transdermal drug products, Ointments, Gels,
Apparatus 5

Paddle over-disk
Emulsion
Transdermal drug products, Ointments, Gels,

Apparatus 6

Rotating Cylinder
Emulsion

Extended-release drug products, Transdermal
Apparatus 7

Reciprocating holder
Patches, Ointments, Gels, Emulsion
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Figure 4: Schematic illustration of apparatus 1 and apparatus 2
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Figure 5 shows the stirring basket elements of dissolution apparatus 1. The apparatus has a basket
on the bottom of the shaft with 37 ±3 mm, made of stainless steel. At the bottom of the basket a
mesh with 25 ±3 mm diameter. The figure shows the dimensions of the each part of the shaft and
basket and the position of the each stirring elements. These are the USP requirements for the
instrumentation of the dissolution apparatus 1. A dosage unit is placed in a dry basket at the
beginning of the test. The distance between the bottom of vessel and bottom of the flask is 25 ± 2
mm is required.
Figure 6 shows the stirring for schematic diagrams of dissolution apparatus 2. This apparatus is
similar to the apparatus 1, as the only difference is a paddle used instead of a basket. This apparatus
is the most widely used to develop a dissolution method in the pharmaceutical industry. The
specifications of the shaft and the paddle are mentioned in detail in the figure. The distance
between the bottom of paddle and bottom of the flask is 25 ± 2 mm is required. The total length of
the paddle is required to be 74-75 mm with a thickness of 4 ± 1 mm.
The specifications of other USP apparatus are specified in general chapter Drug Release<724>.
[23] The general chapter <1092> the dissolution of Procedure: Development and Validation were
published in 2001. The authors proposed that the chapter contains detailed information not only
on the development of dissolution tests to supplement the information that was in <1088> but also
on the validation procedures particular to dissolution testing. [24] As a result of these regulations
of the past fifty years, the number of USP monographs has exponentially increased. In 1970 there
were only twelve monographs. [25] In 2011 there were 740 dissolution USP monographs and in
the recently updated version of USP has 4900 USP monographs.
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Figure 5: USP apparatus 1 basket stirring elements (© 104 U.S. Pharmacopeial
Convention, Used with Permission)
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Figure 6: USP apparatus 2 specifications (© 104 U.S. Pharmacopeial Convention, Used
with Permission)
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Another most widely used dissolution apparatus in the pharmaceutical industry is USP Apparatus
4, Flow-through cell. It was first appeared in 1957 and developed by FDA. [26] The method was
adapted by USP, European Pharmacopeia, and Japanese Pharmacopeia, and the flow through cell
became an official apparatus as USP apparatus-4. The system consists of a reservoir containing
dissolution medium, a pump that forces the medium upwards through the vertically positioned
flow-cell and a water bath to control the temperature in the cell. Different types of cells are
available for testing different dosage forms. Usually, bottom cone of the cell is filled with small
glass beads (about 1 mm diameter) and the dosage unit is placed on top of the beads. Peristaltic or
pulsating pistons are used in the pumps.
Dissolution testing using apparatus 4 continues to grow in popularity. Many pharmaceutical
companies in the United States and throughout the world are currently developing new methods
utilizing apparatus 4 and become more widespread. In the dissolution method development
different variations such as the size of the cell, flow rate, filter size and media with pH change can
be varied with difficulty in apparatus 1 and 2. This technique is useful for the low solubility and
rapidly degrading drugs. [27] Two different types of configurations can be used: an open loop or
closed loop where dissolution media is circulating through drug sample. In the open loop method,
the dissolution media flows through a cell containing the drug sample and goes into the waste after
sampling as it flows in one direction only. [28]
Figure 7 shows all parts of the dissolution apparatus 4. The dissolution medium is placed in a
covered flask from where the medium passes to the cell with the help of a pump. The flow is in
the upward direction, so a pump is required. The cell contains the dosage unit, through which
dissolution media flows and passes through the filtration unit which is placed on the top of the cell
and finally collected in a waste flask or circulates again for a closed system.
20

Figure 7: Schematic diagram of flow-through cell apparatus-4
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1.5

Infrared Spectroscopy

Infrared spectroscopy (IR) is performed using wavelengths, 4000 cm-1 to 400 cm-1, of the
electromagnetic spectrum. Additionally, the IR portion of the electromagnetic spectrum is divided
into three regions; near-infrared, mid-infrared and far-infrared. The near-infrared energy is
approximately in the region between 14000 to 4000 cm-1 and can excite overtone or harmonic
vibrations. The mid-infrared energy is approximately in the region between 4000 (2500 nm) to
400 cm-1 (2500 nm) and can be used to study the fundamental vibrations of structures. The farinfrared region is approximately in the region between 400 to 10 cm-1 and can be used to study to
rotations of structures. [29] [30] With IR spectroscopy, different functional groups absorb at
different IR bands or regions. Thus, this technique can help identify and even quantify organic and
inorganic molecules.

Figure 8 shows the infrared spectrum of a sample can be obtained by passing a beam of infrared
light through the sample. The light passes through a beam splitter, which sends the light in two
directions at right angles. One beam goes to a stationary mirror then back to the beam splitter. The
other goes to a moving mirror. The motion of the mirror makes the total path length variable versus
that taken by the stationary mirror beam. When the two meet up again at the beam splitter, they
recombine, but the difference in path lengths creates constructive and destructive interference: an
interferogram.
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Figure 8: FT-IR schematic diagram
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A Fourier transform instrument can be used to measure how much energy was absorbed by the
sample over the entire wavelength range. [31] The interferogram represents the light output as a
function of mirror position. The FT-IR raw data is processed to give the actual spectrum of light
output as a function of wavenumber. The FT-IR system can produce both transmittance and
absorbance spectrum. Molecules absorb IR radiation and excite to higher energy states. The IR
frequency matches with the natural vibrational frequencies of the molecule. Only those bonds that
have a dipole moment are capable of absorbing IR radiation. Symmetric bond such as those of H2
or Cl2 don does not absorb IR radiation. [32]

1.5.1 Attenuated Total Reflectance-Infrared (ATR-IR) spectroscopy
Attenuated Total Reflectance generally allows qualitative or quantitative analysis of solid and
liquid samples with little or no sample preparation, greatly improves the rate of analysis. The main
benefit of ATR sampling comes from the very thin sampling path length or depth of penetration
of the IR beam into the sample. This is in contrast to traditional FT-IR sampling by transmission
where most of the time the sample must be diluted with an IR transparent salt (e.g. KBr), pressed
into a pellet or pressed to a thin film, prior to analysis to minimize absorption and reflection by the
sample. [33]
In ATR a beam of infrared light is allowed to interact with the sample and the beam gets internally
reflected as it bounces through a crystal, changes relative to a background signal are recorded by
the instrument. An optically dense crystal (e.g. Diamond, Zinc selenide or Germanium) with a
high refractive index (typically refractive index values between 2.38 and 4.01) is used and the
infrared beam is allowed to impact at a certain angle. The most frequently used small crystal in
ATR is diamond, because it has the best durability and chemical inertness.
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Figure 9 shows that a beam of infrared light is directed onto a crystal with a high refractive index
at a certain angle. An evanescent wave is formed due to the internal reflectance which penetrates
out of the crystal and passes through the sample which is in contact with the crystal. However, the
evanescent wave moves only 0.5 µ to 5 µ out of the crystal making it mandatory for the sample to
be in very good contact with the crystal. The evanescent wave is attenuated in the regions where
the sample absorbs energy and the altered wave is reflected back to the IR beam, which then exits
the opposite end of the crystal and is sent to the detector of the spectrometer which ultimately gives
an IR spectrum after processing.
The following experimental factors that affect the quality of final spectrum are the refractive
indices of the ATR crystal, the angle of incidence of the IR beam, the depth of penetration, the
wavelength of the IR beam, the number of reflections and ATR crystal characteristics. ATR
provides excellent quality data in conjunction with the best possible reproducibility of any IR
sampling technique. ATR allows faster sampling, improved sample to sample reproducibility and
minimizing user to user spectral variation.
Figure 10 shows the in-situ FT-IR instrument on which the research has been done. The FT-IR
instrument is the ReactIRTM iC10, from the Mettler Toledo. The FiberConduit™ is comprised of
flexible IR transparent silver chloride/silver bromide optical fibers. The fiber optic probe interface
(AgX 9.5 mm x 1.5 m fiber (Silver Halide)) contains a diamond tip-DiComp ATR crystal. The
enlarged view of the tip of the probe, works with ATR technique.
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Figure 9: A multiple reflection ATR system
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Figure 10: A representation of ATR with in-situ FT-IR (Adopted from Mettler Toledo)
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Recent use and application of the ATR-IR spectroscopy has increased in pharmaceutical industry,
especially in the region of the Mid-IR and the Near-IR. [34] Near-IR spectroscopy has gained
acceptance in the pharmaceutical industry for analysis of incoming raw materials and finished
dosage forms in the last century. [35] The determination of the multiple parameters from a single
near-IR spectrum is the most valuable attribute. One recent application of near-IR is in the
prediction of dissolution behavior of pharmaceutical tablets with near-IR imaging. [36] Wendy
and Zhuangji described detection and quantitation of volatile organic contaminants in water using
ATR-IR technique. [37]

The FT-IR Imaging technique was first introduced in 1997. The technique has been applied to
study many different systems from all facets of science, from areas such as polymer diffusion and
dissolution. [38] Van der Weerd and his colleagues described the design and implementation of a
new cell, which allows the study of drug release from tablets by macro-FT-IR ATR imaging with
a diamond ATR accessory. Tablet formulation can be impacted directly on the ATR crystal. The
authors explain that various components in the tablet can be determined FT-IR imaging. [39] Wray
and his colleagues explored the novel application of FT-IR imaging to study the dissolution of
delayed release and pH resistant compressed coating pharmaceutical tablets. It was used to
accurately determine the swelling of the hydroxypropyl cellulose core and its relation the rate of
water ingress.
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In the pharmaceutical industry, there are two main solid oral dosage forms: tablets and capsules
and others as well. The tablets or capsules are immersed in an aqueous solution for dissolution
testing, and the concentration of the active ingredient is monitored as a function of time.
Dissolution testing alone provides limited information on chemical processes that take place within
a dissolution vessel, because of the limited capabilities of the techniques that are used during
dissolution. Most dissolution analysis is carried out using ultra-violet and visible spectroscopy
which only gives concentration as a function of time. high-performance liquid chromatography is
used to separate multi-component drugs but still utilizes UV/Vis detection. [40]

One of the challenges in the industry is faced with is to increase an understanding of the
mechanisms governing dissolution. The current approach relies heavily on a data-driven approach.
To have a better understanding of dissolution, dissolution chemists need to explore other
applications that could give insight into what is happening inside of the vessel. This research
focuses on using ATR mid-infrared spectroscopy as an in situ technique to monitor and study the
dissolution of pharmaceutical tablets. The fiber-optic probes for reaction monitoring and
spectroscopy have been used as an important device in research. The flexible fiber optical probes
and spectroscopic software have enhanced the development of real-time applications. However,
recently, on-line methodologies have been used for obtaining accurate data during the dissolution
process.
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1.6

Drugs used in this Research

As discussed earlier, this research is conducted using in situ FT-IR technique to monitor the
dissolution process. For this research, solid dosage form such as tablets were selected which were
available over the counter and easily available, these are acetaminophen, aspirin, salicylic acid and
Loratadine which are shown in Figure 11.

1.6.1 Acetaminophen
Acetaminophen (paracetamol) has been widely used for nearly a century and is currently one of
the most commonly used medications in the United States. Acetaminophen is an effective and
well-tolerated analgesic and antipyretic agent when used as indicated. [41] Acetaminophen is a
synthetic, nonopiate, centrally acting analgesic derived from p-aminophenol and it is also a
degradation product. It is reported to have significant nephrotoxic and teratogenic effects, therefore
its dosage should be strictly controlled. [42] [43] Drug metabolism plays a key role in
acetaminophen-induced hepatotoxicity. Acetaminophen metabolism occurs primarily in the liver,
where the drug undergoes glucuronidation sulfation by UDP-glucuronosyltransferases and
sulfotransferases, respectively.
Figure 12 shows the FT-IR spectra of a standard solution of acetaminophen and phosphate buffer.
The blue line is for the buffer and the yellow line is for acetaminophen which shows peak at 1246
cm-1 for the analysis, corresponding to C-N stretch. For the research, the standard IR spectra of
acetaminophen collected via FT-IR were confirmed and compared with standard spectra, which is
collected from SDBS database for acetaminophen shown in Figure 13. [44] One more confirmation
test has been performed by studying calibration of acetaminophen using different concentrations.
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Figure 11: Structures of drugs used in this research
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Figure 12: In-situ FT-IR spectra of acetaminophen
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Figure 13: IR spectra of acetaminophen from SDBS database (Adopted from reference 45)
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1.6.2 Aspirin and Salicylic Acid
Aspirin is unique in its history and has many important roles in drug therapy. Aspirin is a pro-drug
and known to decrease pain. It fights pain and inflammation by blocking the action of an enzyme
called cyclooxygenase which inhibits the formation of prostaglandins, [45] which signal an injury
and trigger pain. Aspirin also inhibits the formation of prostaglandins. This results in the inhibition
of blood clots which could cause a heart attack or stroke. Aspirin was first synthesized by the
German chemist Felix Hoffmann (1868-1946) in the laboratories of Farbenfabriken Bayer,
Elberfeld, Germany in 1897. [46] Salicylic acid was used prior to aspirin, has several bad flaws as
a medicine. It has a bad taste, cause stomach irritation and presents other side effects spurred
researchers to look for other derivatives. The intent was to keep salicylic acid efficacy without the
disadvantages it posed. Acetylation of the hydroxyl group was one of the logical modifications.
This eventually led to the synthesis and discovery of aspirin.
Felix Hoffman used acetic anhydride for preparation of aspirin. Figure 14 shows the formation of
aspirin from salicylic acid and acetic anhydride. Salicylic acid can react with ethenone and acetyl
chloride to form aspirin. This is the general synthesis pathways for the formation of salicylic acid
that were investigated back in the late 1800’s. [47]
A chemical reaction of particular relevance to aspirin’s stability in biological fluids is hydrolysis.
There are two types of hydrolysis which are based on the pH. Figure 15 shows the acid catalyzed
mechanism, if the proton source is hydronium (H3O+), the catalysis is termed specifically acid
catalysis. The source of the proton is a dissociated acid and the substrate (the ester) is already
protonated in the rate-limiting (slow) step of the reaction.
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Figure 14: Synthesis of aspirin in 1800’s [48]
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Figure 16 shows the base catalyzed aspirin hydrolysis mechanism. Any undissociated acid (if
present) does not appear in the rate-limiting step. [48] In base catalysis the base is hydroxide (HO−)
and the substrate is attacked by hydroxide in the rate-limiting step of the reaction. There are no
other bases (such as the conjugate base of an acid) in the rate-limiting step. The spontaneous
process shows water acting as the nucleophile attacking a neutral substrate. [49]

Figure 17 is the FT-IR spectra of a standard solution of aspirin, salicylic acid and buffer. The blue
line is for salicylic acid, the green one is for buffer solution and the pink line is for aspirin. Aspirin
shows peak at 1205 cm-1 for the analysis, corresponds to C-O stretch and salicylic acid shows peak
at 1388 cm-1 for the analysis, corresponds to C-C stretch in the aromatic ring, selected for the
further analysis. The most interesting part of this study is that that, these picks are not interfering
with each other that make analysis very clear.

For the research, the standard IR spectra of aspirin and salicylic acid collected on FT-IR were
confirmed and compared with standard spectra, which is collected from SDBS database for aspirin
shown in Figure 18 and for salicylic acid shown in Figure 19. [50] Additional confirmation test
perform was done by performing calibration of aspirin and salicylic acid at different
concentrations.
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Figure 15: Acid-catalyzed aspirin hydrolysis
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Figure 16: Base-catalyzed aspirin hydrolysis
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Figure 17: In-situ FT-IR spectra of aspirin and salicylic acid
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Figure 18: IR spectra of aspirin from SDBS database (Adopted from reference 51)
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1388 cm-1

Figure 19: IR spectra of salicylic acid from SDBS database (Adopted from reference 51)
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CHAPTER– 2
DISSOLUTION AND NONLINEAR BEHAVIOR OF
ACETAMINOPHEN
2.1

Introduction

Dissolution testing can give an in-vitro snapshot of how the drug product may behave in-vivo. As
a result, the number of dissolution methods in the United States Pharmacopeia has grown
substantially. [51] The potential impact of a new analytical technique that permits in-situ analysis
of multiple active ingredients during dissolution testing is profound.
This section focuses on the dissolution of over-the-counter acetaminophen tablets. The study of
the dissolution of acetaminophen was done earlier by conventional methods. [52] These
conventional methods need manual sampling which disturbs the dissolution process during
analysis by the traditional way using UV or HPLC. [53] The main purpose of this study is to
perform dissolution and analysis of acetaminophen tablet by a novel technique using in-situ FTIR which is compared to UV and HPLC.

2.2

Experimental Section

2.2.1 Chemicals and materials
Acetaminophen reference material used in this study (batch no. 104K0154) was purchased from
Sigma-Aldrich (St. Louis, MO). Acetaminophen tablets (Tylenol extra strength batch no. SLA175)
were purchased from a local pharmacy. Acetaminophen extended release tablets (Tylenol Arthritis
Pain batch no. 09FMC085) were purchased from a local pharmacy. Methanol, acetone and
acetonitrile (HPLC grades) were purchased from Pharmaco-Aaper (Brookfield, CT). Sodium
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hydroxide (batch no. 064214BH), used to prepare the pH buffered solutions, was purchased from
Sigma-Aldrich (St. Louis, MO). Potassium phosphate monobasic (batch no. 103K0060), used to
prepare the pH buffered solutions, was purchased from Sigma-Aldrich (St. Louis, MO). Sodium
chloride crystals (batch no. J39602) was purchased from Mallinckrodt Chemicals (England, UK).
All solutions were prepared using water treated by a Milli-Q plus Millipore purification system
(Milford, MA). All purified water aliquots have a resistivity of not less than 18 MOhm-cm-1.

2.2.2 Instrumentation
All chemicals were weighed on a Mettler Toledo balance (Washington Crossing, PA) PB303
Delta-Range® and AG204 Delta-Range®. The pH of the buffer was measured on pH meter by
VWR SympHony (Radnor, PA) SB70P. Dissolutions were carried out on the Easy MaxTM 102 by
Mettler Toledo. HPLC analysis was performed on a Hewlett-Packard 1050 HPLC, with Chem
Station software. All UV measurements were carried out using a Hewlett-Packard UV instrument
(model no. 8452A diode array). The UV instrument was operated using Olis Spectralworks. All
manual dissolutions were tested using a Van-kel Dissolution Bath (model no. 700 and serial no.
31-214-1296).
In-situ FT-IR analysis was performed on a Mettler Toledo iC 10 ReactIR, with iCIR versions 3.0
and 4.0 software. The ReactIR™ iC10 FTIR instrument is composed of a Mercury Cadmium
Telluride detector (liquid nitrogen cooled) and a FiberConduit™. The FiberConduit™ is
comprised of flexible IR transparent silver chloride/silver bromide optical fibers. The fiber optic
probe interface (AgX 9.5 mm x 1.5 m Fiber (Silver Halide)) contains a diamond tip-DiComp ATR
crystal. The resolution was set to 8 wavenumbers. The optical range used by the system is: 1900
cm-1 to 650 cm-1. The gain adjustment was set to normal (1x) and the apodization method was set
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to Happ-Genzel. The system uses compressed air (house air, filtered and dehumidified) to purge
the optics.

2.2.3 Potassium phosphate buffer (pH 5.8)
Potassium phosphate buffer (0.2 M) was prepared as per the USP procedures of buffer solutions.
[54] For 200 mL of buffer 50 mL of 0.2 M potassium phosphate monobasic solution and 3.6 mL
of 0.2 M sodium hydroxide solution were used. The volume was made up with deionized water to
200 mL and then the pH was measured.

2.2.4 Acetaminophen solutions for calibration
For the calibration study, 137.5 mg of acetaminophen (99 %) was weighed and dissolved in 100
mL of phosphate buffer pH 5.8 and used as stock solution. Then 14 dilutions were made using the
stock solution. For dilution added 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 mL stock solution
by using volumetric pipettes in each 25 mL volumetric flask and made volume with phosphate
buffer pH 5.8, then concentration of each flask was 0.0275, 0.055, 0.0825, 0.110, 0.165, 0.220,
0.275, 0.330, 0.385, 0.440, 0.495, 0.550, 0.605 and 0.660 mg/mL respectively analyzed samples
on UV spectroscopy and in-situ FT-IR.

2.2.5 Standard solutions
The standard solution of acetaminophen was prepared by weighing 55 mg of acetaminophen and
dissolved in 100 mL of phosphate buffer pH 5.8 resulting concentration 0.55 mg/mL.

2.2.6 Dissolution of acetaminophen (Extra Strength Tylenol)
Tylenol tablets 500 mg of acetaminophen (Label Claim) were tested in pH 5.8 phosphate buffer as
per acetaminophen USP monograph. [55] Dissolutions were conducted using vessel volumes of
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900 mL and at 37.0 °C on Van-kel dissolution bath. All dissolutions were conducted using USP
Apparatus Type II (paddles) with an agitation speed of 50 rpm.

2.2.7 Dissolution of acetaminophen (Arthritis Tylenol)
Tylenol (Arthritis Pain) tablets 650 mg of acetaminophen (Label Claim) were tested in pH 5.8
phosphate buffer 64 mins. Dissolutions were conducted using vessel volumes of 900 mL and at
37.0 °C on Van-kel dissolution bath. All dissolutions were conducted using USP Apparatus Type
II (paddles) with an agitation speed of 50 rpm.

2.2.8 In-situ FT-IR analysis
For the calibration as well as the dissolution of acetaminophen experiments, data treatment was
carried out using the following methodology: The data was first subjected to baseline correction.
The absorption band at 1246 cm-1 (corresponding to the C-N stretch) was selected for
acetaminophen. The peak area was calculated using a two-point baseline correction set at 1265
cm-1 and 1230 cm-1. The ATR-IR system was configured to collect spectra every two minutes at
room temperature.

2.2.9 HPLC analysis
1.0 mL aliquots were collected during dissolution testing after a time interval (2, 4, 8, 16, 32 and
64 mins) and filtered using a syringe filter (0.45 µm). The column used was Phenomenex Luna
5µm

Phenyl-Hexyl

column

(4.6

x

150

mm),

with

mobile

phase

70/30/1

(methanol/water/trifluoroacetic acid). The flow rate was set 0.5 mL/min, isocratic mode, with an
injection volume 10 µL and the absorbance set at 296 nm.
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2.3

Results and Discussion

2.3.1 Calibration of acetaminophen
The USP monograph specifies the pH 5.8 phosphate buffer as the medium of choice for
acetaminophen dissolution. Hence all standard diluted solutions were prepared in phosphate buffer
pH 5.8. Based on the in-situ FT-IR spectra and UV/Vis data obtained for acetaminophen, at low
concentrations (≤ 0.11 mg/ml), the relationship between absorbance and concentration is
effectively linear (r2= 0.9967). However, non-linear behavior was observed for both IR (r2=
0.9985) and UV-Vis (r2= 0.9981) methods at higher concentrations.

Figure 20 shows the calibration data of acetaminophen standard solutions. The calibration was run
from 0.05 to 0.66 mg/mL concentration of acetaminophen. 2nd order polynomial curve with r2=
0.999 was observed for both FT-IR as well as UV/Vis spectroscopy.

Figure 21 shows the calibration data of acetaminophen low standard solutions. The calibration data
was from 0.05 to 0.11 mg/mL concentration of acetaminophen. The calibration is a linear, which
ran on the UV/Vis spectroscopy with r2= 0.997.

Both methods can be modeled using second-order polynomial equations and has been confirmed
after multiple replications. [56] The hypothesis has established that it is because of the dimerization
of the acetaminophen. The proposed statement is that in the higher concentrations the
acetaminophen molecules form dimers. The detailed experimentation is discussed in the later part
of this section.
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Figure 20: Non-linear graph for different levels of acetaminophen reference standards
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Acetaminophen reference standards in 5.8 phosphate buffer,
UV/Vis absorbance at 296 nm, 5-20% dilutions
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Figure 21: Linear calibration graph of acetaminophen at low concentrations
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2.3.2 Dissolution of Extra Strength Tylenol
At the initial stage of the research, dissolution of extra strength Tylenol was performed using
UV/Vis spectroscopy to understand the dissolution procedure and analysis. As per the procedure
which is discussed in the experimental section, dissolution was performed three times using 5
vessels with a Van-Kel dissolution bath. Aliquots were collected for UV/Vis analysis after 2, 4, 8,
16, 32 and 64 mins respectively. The percent dissolution was calculated by using following
formula.
% Dissolution =
×

Absorbance of Sample
Standard Mass
×
Absorbance of Standard Standard Volume

(9)

Vessel Volume
× Standard Purity × 100
Potency

Figure 22 shows the dissolution of extra strength Tylenol. The tablets were dissolved in 15-20
mins and all vessel data overlapped as per expectations. Maximum drug dissolved after 60 mins
were 91%.
It is noticed that percent dissolution observed during this study is slightly lower than percent
dissolution observed during other experiments carried out with Extra strength Tylenol in last few
decades. This observation could be due to the hypothesis of the calibration of acetaminophen
which showed polynomial curve at increased concentration.
Figure 23 shows that recalculated percent dissolution of acetaminophen by using polynomial
equation from the calibration graph and observed that the percentage of dissolution has increased
to 96%. Based on these calculations and results, it confirmed the hypothesis at higher
concentrations acetaminophen molecules form dimers.
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% Dissolved

Dissolution data 5 vessles of Acetaminophen in 5.8 phosphate
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Figure 22: Dissolution of acetaminophen
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Figure 23: Dissolution of acetaminophen after polynomial calculations
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70

2.3.3 Dissolution of Tylenol (Arthritis Pain)
After studying the UV/Vis analysis and dissolution procedures, the research was extended towards
the main goal of the thesis which was the in-situ FT-IR dissolution and its comparison with HPLC.
Tylenol has a long lasting effect on the arthritis pain and hence the dissolution was performed for
8 Hrs. Aliquots were taken throughout the experiment and analyzed to compare the in situ FT-IR
method with HPLC and UV/Vis methods.

The results from the in situ FT-IR, UV/Vis and HPLC systems are overlaid as shown in Figure 24.
An excellent correlation was observed between these three methods. The amount of released
acetaminophen by HPLC (yellow Line) and UV/Vis (green Line) is little higher than the in-situ
FT-IR (Orange line) in the early part of the dissolution from 30 mins to 2 hr. This might be because
of the dissolution-in-dissolution concept which happens in the HPLC and UV/Vis vials; fine
particles of acetaminophen can appear after filtration in the vial was dissolved again in the
dissolution media upon storage of sample for the analysis and showed higher concentration than
the in-situ FT-IR. This shows the advantage of the novel technique in-situ FT-IR, which avoids
further dissolution of the drug in the sample vial upon wait time for analysis.
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Extended Release Acetaminophen By UV, HPLC and in-situ FT-IR
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Figure 24: Dissolution data of acetaminophen (Arthritis pain)
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2.4

Non-Linear behavior of Acetaminophen

In acetaminophen research, it has been observed from the calibration data that acetaminophen has
a non-linear behavior. The calibration study was done by UV-vis spectroscopy and in-situ FT-IR
from concentration ranges from 0.005 mg/mL to 0.66 mg/mL. At the lower concentration the
calibration showed a linear graph in Figure 21, but at higher concentrations, it is non-linear as
shown in Figure 20. On searching for literature explaining this behavior specifically for
acetaminophen, it was found that acetaminophen has a tendency to form dimer with respect to pH
of the solution. [57] [58] The polymorphism study of acetaminophen showed that the interplay of
molecular flexibility and hydrogen bonding manifested in the monoclinic and orthorhombic
polymorphs of acetaminophen and with the X-ray crystallographic study has confirmed. [59] [60]
There is evidence about the formation of acetaminophen hemi adducts due to the formation of
chains for acetaminophen molecule linked via OH…O=C interaction or NH….O=C interaction.
[61]

In this research, the acetaminophen was in solution form, where it was dissolved in phosphate
buffer pH 5.8. There is no evidence which claiming the formation of a dimer in these conditions.
Because of the importance of acetaminophen as medicine, there is a need to better understand this
unusual behavior of acetaminophen. Based on the observed results, the hypothesis was proposed
that the non-linear behavior is because of the dimerization showed in reaction 1 or aggregation of
the acetaminophen molecules showed in reaction 2.
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Reaction 1

Reaction 2

The main focus is to study the non-linear behavior of acetaminophen by different instrumental
techniques and by studying colligative properties to calculate the number of moles of
acetaminophen in the buffer solution.
Investigation of the dimerization of acetaminophen has been performed by different techniques,
Infrared spectroscopy (IR), Nuclear Magnetic Resonance spectroscopy (NMR) and colligative
properties in that by vapor pressure osmometry and freezing point depression.
Investigation of dimerization of acetaminophen is possible by IR spectroscopy. It can identify
interactions that occur as a result of hydrogen bonding which leads to dimeric and oligomeric
structures shown in Reaction 1 and Reaction 2. The carbonyl group present is around 1600-1700
cm-1 wave numbers. There is literature, which describes the use of IR spectroscopy to detect
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dimerization of carboxylic acid structures. This suggests that this technique can be used to study
acetaminophen in nonpolar solvents. [62] [63] [64] Literature gave evidence that, because of
formation of dimer, which creates a new hydrogen bond and shows a new broad peak for the dimer
in the region of 3300 cm-1-3700cm-1. [65] IR Spectroscopy has been used to identify the phosphoric
acid dimerization a well-known example of dimerization. [66] [67]
Another common example for the study of the nonlinear behavior is benzoic acid which is shown
in reaction 3.
Reaction 3

The investigation of the benzoic acid dimer was done by IR spectroscopy. They observed a
broadening and shift of the carbonyl stretching frequency. [68] Literature studies provide evidence
about the benzoic acid dimer study. [69] [70] [71] Literature study of dimerization shows the IR
spectroscopy study will be useful for investigation and confirmation.

The non-linear behavior of acetaminophen which is because of the aggregation or dimerization of
molecules can be investigated by NMR. That gives the information about the chemical shift of
hydrogen and carbon peak which moves to downfield. [72] The proton transfer in the benzoic acid
dimer was measured by the NMR. [73] The literature showed that the study of dimerization and
the oligomerization can be analyzed by NMR, even quantitative analysis can be done by NMR.
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[74] [75] [76] Literature suggested another way to determine the dimer formation of
acetaminophen in phosphate buffer by NMR analysis.

The presence of one or more solutes alters the ability of the solvent molecules to interact, reducing
their freedom of movement, thus the ability to move from liquid to solid is altered. These changes,
which collectively are referred to as colligative properties, are dependent on the total number of
particles present in the solution. [77] One of the colligative property, osmotic pressure a direct
measurement of the molar concentration of total solutes in an aqueous solution. Osmotic pressure
is defined as the force which would be required to resist movement of solvent across a membrane
which is permeable to the solvent but not to the solute molecules. A solute particle can be a
molecule or an ion or an aggregated species such as dimer that can exist discretely in solution.
Since osmotic pressure is directly related to the total molar concentration of solute, there is a direct
and linear relationship between osmotic pressure. [78] [79]

Another excellent way to determine the molecular weight of dissolved acetaminophen is by
measuring the vapor pressure of the solution. By osmometry, one can measure the vapor pressure
of the acetaminophen solution and can calculate the molecular weight and then moles of the
solution.

Thus, if acetaminophen dimerizes or oligomerizes, the measured molar mass will be larger than
the molar mass of the monomer of 151.16 g/mol. However, it is expected that the measured molar
mass will be a weighted average of monomer, dimer and oligomer species that will be present.
Thus M = x (monomer) + y (dimer) + z (trimer) + zz (tetramer +…. Robert performed some
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forensic laboratory experiments to calculate the weights of drugs and diluents by osmometry,
which gave the motivation of performing the experiments to calculate the moles of acetaminophen.
[80]

A solution freezes at a lower temperature than does the pure solvent. This phenomenon is called
freezing point depression. The freezing point depression of a solution is a colligative property of
the solution which is dependent upon the number of dissolved particles in the solution. The higher
the solute concentration, the greater the freezing point depression of the solution. [81] The freezing
point values are determined from the cooling curves obtained by recording the temperature as a
function of time. [82] Another application of this method is mainly in the food industry to study
the thermodynamic properties of frozen food and fruits. [83] [84] Freezing point depression is used
to determine the molecular mass of polyols which avoids the interference by water, by using
acetophenone as a solvent having freezing point depression 20oC. [85]

After reviewing all this literature performed the different experiments on IR, NMR and for
colligative properties such as vapor pressure osmometer and Freezing point depression as well.
The results from these experiments could not support the hypothesis that at higher concentrations
acetaminophen molecules form dimer. There is a lack of any evidence to explain or confirm the
dimerization of acetaminophen as per the proposed hypothesis.
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2.5

Conclusion

The in-situ infrared spectroscopy is a viable alternative for measuring dissolution profiles of
pharmaceutical tablets. The in-situ FT-IR system was found to be impressive and validated by
comparing dissolution profile using UV/Vis and HPLC. The method was calibrated with
acetaminophen standard solutions ranging from 0.05 mg/mL to 0.66 mg/mL, with r2=0.998. The
percent dissolution of acetaminophen was found in the range of 95-97 % by all three techniques.

The in-situ FT-IR has great advantage of minimizing the manual efforts required for manual
sampling of dissolution. On the contrary, UV/Vis and HPLC methods require laborious manual
sampling. With the current configuration of the in-situ FT-IR instrument, this analysis is limited
by the sensitivity and wavelength range of the in-situ fiber optic probe. However, since this chapter
successfully demonstrates the versatility of this novel application of in-situ FT-IR spectroscopy.

Unsatisfactory results were observed for the hypothesis of the dimerization of acetaminophen. As
part of this study, multiple experiments were designed and performed on the respective instruments
(IR, NMR and using colligative properties such as vapor pressure osmometer and freezing point
depression) for the dimerization study of acetaminophen. But still, there is a lack of evidence to
support the proposed dimerization hypothesis.
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CHAPTER - 3
DISSOLUTION AND HYDROLYSIS STUDY OF ASPIRIN
3.1

Introduction

This section focuses on monitoring the dissolution and hydrolysis of over the counter tablet
acetylsalicylic acid (aspirin) under acidic conditions by In-situ FT-IR spectroscopy using
attenuated total reflectance infrared probe (ReactIR). The acetylsalicylic acid undergoes hydrolysis
to form salicylic acid and acetic acid. [86] The equation of aspirin hydrolysis is written as
mentioned below.
Reaction 4

The majority of the methods for monitoring dissolution utilize UV/Vis spectroscopy. For example,
aliquots are manually withdrawn and analyzed by UV/Vis spectroscopy or HPLC with ultraviolet
detection. However, the sampling process is disruptive to the dissolution profile since the removal
of aliquots from the vessel disturbs the solution. In addition, there are instruments that allow realtime analysis using in-situ UV/Vis probes. For example, fiber optic dissolution testing is used in
the pharmaceutical industry to monitor drug product release. Fiber optic dissolution is also used
for formulation development. [87] Formulators are using these in-situ UV/Vis systems to profile
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and develop drugs faster, instead of conventional techniques where dissolutions are conducted
manually and analyzed offline. The advantage of the fiber optic system is that it allows real-time
data analysis. But the major disadvantage of UV/Vis system is a small range of the analysis that is
200-400 nm, in the case of aspirin and salicylic acid study both peaks overlap of the main maxima
and limits the analysis which needs additional determination for methods. [88]
There is an interest to develop new methods that do not require manual sampling. The use of insitu FT-IR for analyzing aqueous samples is limited by the relatively high concentration of analyte
required for detection. [89] Hence this research investigated the use of in-situ FT-IR spectroscopy
as a potential technique for monitoring and understanding dissolution. The research showed that
dissolution using in-situ FT-IR spectroscopy for the single component as well as multi-component
formulations is useful for monitoring the release profile of each active pharmaceutical ingredient
(API). [90] Thus, there is also an interest in the development of hydrolysis of a prodrug aspirin
while performing dissolution and study kinetics of that process.

3.2

Experimental Section

3.2.1 Chemicals and materials
Acetylsalicylic acid (aspirin) reference material (batch no. 016K0131) was purchased from SigmaAldrich (St. Louis, MO). Salicylic acid reference material (batch no. 04708HE) was purchased
from Sigma-Aldrich (St. Louis, MO). Acetylsalicylic acid 325 mg tablets (Genuine Bayer batch
no. 219050N) were purchased from a local pharmacy. Methanol, acetone and acetonitrile (HPLC
grades) were purchased from Pharmaco-Aaper (Brookfield, CT). Sodium chloride crystals (batch
no. J39602) was purchased from Mallinckrodt Chemicals (England, UK). Hydrochloric acid (batch
no. H44032) was purchased from J.T. Baker (Central Valley, PA). Sodium acetate crystals (batch
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no.05816HD, potassium phosphate monobasic (batch no. 103K0060) and sodium hydroxide
(batch no. 06414BH) were purchased from Sigma-Aldrich Chemicals (St. Louis, MO). Glacial
acetic acid (batch no. 971666) was purchased from Fisher Chemicals (Waltham, MA). All
solutions were prepared using water treated by a Milli-Q plus Millipore purification system
(Milford, MA). All purified water aliquots have a resistivity of not less than 18 MOhm-cm-1.

3.2.2 Instrumentation
All chemicals were weighed on a Mettler Toledo balance (Washington Crossing, PA) PB303
Delta-Range® and AG204 Delta-Range®. The pH of the buffer was measured on a VWR
SympHony (Radnor, PA) SB70P pH meter. Dissolutions were carried out on the Easy MaxTM 102
by Mettler Toledo. HPLC analysis was performed on a Hewlett-Packard 1050 HPLC, with Chem
Station software. In-situ FT-IR analysis was carried on a Mettler Toledo iC 10 ReactIR, with iCIR
versions 3.0 and 4.0 software.

3.2.3 Simulated gastric fluid
Simulated gastric fluid was prepared with hydrochloric acid and sodium chloride as per USP buffer
procedure. [91] 2 g of sodium chloride was dissolved in 100 mL of deionized water, in that 7 mL
HCl was added and then volume made up to 1000 mL by adding deionized water, and then
measured pH of that solution and was adjusted to 1.2.

3.2.4 Sodium acetate buffer
Sodium acetate buffer was prepared with glacial acetic acid and sodium acetate anhydrous as per
the USP buffer procedures. [92] 2.99 g of sodium acetate was dissolved in 100 mL of deionized
water, in that 1.66 mL glacial acetic acid was added and then volume made up to1000 mL by
adding deionized water and then measured pH of that solution and was adjusted to 4.5.
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3.2.5 Potassium phosphate buffer
Potassium phosphate buffer (0.2 M) was prepared with monobasic potassium phosphate and
sodium hydroxide as per the USP buffer procedures. [93] First potassium phosphate solution was
prepared by weighing 27.22 g of monobasic potassium phosphate and dissolved in 100 mL of
deionized water and diluted with up to 1000 mL. Next sodium hydroxide solution was prepared
by weighing 8 g of sodium hydroxide dissolved in water and made volume up to 100 mL. For
phosphate buffer added 50 mL of monobasic potassium phosphate solution in a 200 mL volumetric
flask then added 22.4 mL of sodium hydroxide solution and then added water to make a volume.
Finally measured the pH of this solution and was adjusted to 6.8.

3.2.6 Aspirin solution for calibration
Aspirin stock solution was prepared by dissolving 500 mg of aspirin in 100 mL of simulated gastric
fluid (pH 1.2), sodium acetate buffer (pH 4.5) and phosphate buffer (pH 6.8). To prepare a
calibration curve, nine dilutions were made by using this stock solution by adding 1.00, 2.00, 3.00,
4.00, 5.00, 6.00, 7.00, 8.00 and 9.00 mL to 10.00 mL volumetric flasks respectively and diluting
to volume with respective buffer solution. The concentration of aspirin in each flask was 0.500,
1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00 and 4.50 mg/mL as well as 3.62, 7.24, 10.9, 14.5, 18.1, 21.7,
25.3, 28.9 and 32.6 mM respectively. Aspirin starts hydrolyzing as it goes into solution, to avoid
or to slow down that process; solutions were placed into an ice bath immediately after the
preparation. As soon as solutions were ready, they were scanned by in-situ FT-IR for the
calibration study at room temperature.
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3.2.7 Salicylic acid solution for calibration
A stock solution of salicylic acid was made by dissolving 500 mg of salicylic acid in 100.00 mL
of simulated gastric fluid (pH 1.2), sodium acetate buffer (pH 4.5) and phosphate buffer (pH 6.8).
To prepare a calibration curve, nine dilutions were made by using this stock solution by adding
1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00 and 9.00 mL to 10.00 mL volumetric flasks
respectively and diluting to volume with respective buffer solution. The concentration of salicylic
acid in each flask was 0.500, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00 and 4.50 mg/mL as well as
2.78, 5.55, 8.33, 11.1, 13.9, 16.7, 19.4, 22.2 and 25.0 mM respectively.

3.2.8 Hydrolysis of aspirin to salicylic acid in test tubes
Prior to the hydrolysis experiments, a qualitative measurement was investigated for determining
the presence of salicylic acid in solution. Acetylsalicylic acid hydrolyzes to salicylic acid in the of
acidic medium. Ferric chloride test was found to be a good qualitative test for phenols. Ferric
chloride in solution gives colors with a number of organic derivatives. The common ones are
phenols, enols, oximes, hydroxamic acids, and some carboxylic acids. It will, however, react with
salicylic acid, which is used to synthesize aspirin, forming an iron-phenol complex. [94] [95] Thus,
adding an aqueous ferric chloride solution to an aspirin solution is a good way to see if there is any
salicylic acid present. The ferric chloride color test is shown below. A small experiment was
performed in that used three vials containing simulated gastric fluid (vial C) as control, aspirin
solution (vial A) and salicylic acid solution (vial S).
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3.2.9 Standard solutions
The standard solutions were prepared by weighing 325 mg of aspirin and 325 mg salicylic acid
and dissolved in 100 mL of simulated gastric fluid, sodium acetate buffer and potassium phosphate
respectively and obtained concentration 3.25 mg/mL.

3.2.10 Dissolution and hydrolysis of aspirin
Bayer Aspirin tablets 325 mg of aspirin (Label Claim) were measured in pH 1.2 simulated gastric
fluid solutions for 1.5 hr., pH 4.5 sodium acetate buffer for 24 hr and potassium phosphate buffer
for 24 hr. Dissolutions were conducted using vessel volumes of 100 mL at 37.0 °C. All dissolutions
were conducted using USP Apparatus Type II (paddles) with an agitation speed of 100 rpm as per
the USP procedure and collected samples for HPLC as well.

3.2.11 In-situ FT-IR Analysis
3.2.11.1

Aspirin analysis

A distinct peak for aspirin without interference was observed. Calibration of aspirin with standard
diluted solutions as discussed in experimental section. For the calibration of aspirin experiments,
data treatment was carried out using the following methodology: The data was first subjected to
baseline correction. The absorption band at 1205 cm-1 (corresponding to the C-O stretch) was
selected for acetylsalicylic acid. The study was done by using three different body pHs such as
simulated gastric fluid (pH 1.2), sodium acetate buffer (pH 4.5) and phosphate buffer (pH 6.8)
which depicts stomach, duodenum and small intestine pHs respectively.
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3.2.11.2

Salicylic acid analysis

A distinct peak for salicylic acid without interference was observed which is shown in Figure 17,
then performed calibration of salicylic acid with standard diluted solutions as discussed in
experimental section. For the calibration of salicylic acid experiments, data treatment was carried
out using the following methodology: The data was first subjected to baseline correction. The
absorption band at 1488 cm-1 (corresponding to the C-C stretch in the aromatic ring) was selected
for salicylic acid. Although a unique absorption at 1161 cm-1 (corresponding to the C-O stretch)
was observed for salicylic acid, 1488 cm-1 was chosen for further analysis because of its higher
intensity. The study was done by using three different body pHs such as, simulated gastric fluid
(pH 1.2), sodium acetate buffer (pH 4.5) and phosphate buffer (pH 6.8) which depicts stomach,
duodenum and small intestine pHs respectively.

3.2.11.3

Dissolution and hydrolysis of aspirin tablet

The dissolution testing was carried out as discussed in the experiment section. The in-situ FT-IR
fiber optic probe collected baseline spectra (blank medium) for the first 30 minutes. A single 325
mg Bayer aspirin tablet was dropped into the vessel containing 100 mL of buffer solution
(simulated gastric fluid pH 1.2, sodium acetate buffer pH 4.5 and potassium phosphate buffer pH
6.8) and the dissolution profiles were collected using in-situ FT-IR spectroscopy. Standard spectra
of pure aspirin and salicylic acid were collected prior to running the dissolutions. These standards
were used to identify the unique peaks of interests for these active drugs. For the aspirin tablet
analysis, the same steps as discussed in calibration analysis were followed.
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For this experiment, data processing is critical to obtain well-resolved spectra. For all in-situ FTIR experiments, 256 scans were collected and co-added for each spectral point and each data point
took about two minutes to complete. The peak of interest was identified (1205 cm-1) and the area
was calculated using a two-point baseline correction. A trend analysis was performed using the
iCIR software on this peak. This provided a plot of absorbance vs. time. This plot was subjected
to smoothing using a 25 point smoothing parameter. After smoothing, and while still in the trend
analysis, the baseline correct routine was performed. Then, the data were exported to Excel.
Further data processing in Excel involved the subtraction of solvent spectra background. A 30 min
set of spectra at the beginning of the experiment were obtained before aspirin pill was added. These
spectra were subtracted from the spectra taken after the pill was dropped to give the final set of
data. Within the final set of data, the area of the 1205 cm-1 peak was calculated at each time point.
Then the plot of area vs. time was performed to give rate information. In addition, using a
calibration curve, peak areas were converted to concentration to provide concentration vs. time
plots.

3.2.12 HPLC analysis
The dissolution aliquots (1.0 mL) were collected after a certain time interval and filtered using
syringe filter (0.45 µm) transferred to an ice bath to prevent further hydrolysis. The column was
used is Phenomenex C18 5 µm Luna column (4.6 x 150 mm), with mobile phase 60/40/1
(methanol/water/trifluoroacetic acid) with 13 min run time. The flow rate was set to 0.5 mL/min,
isocratic mode, with an injection volume 10 µL and absorbance was measured at 300 nm.
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3.3

Results and Discussion

3.3.1 Calibration of aspirin
Based on the IR spectra obtained, aspirin has unique IR bands at 1205 cm-1. Linear regression for
aspirin was calculated by using the area under curve (AUC) calculations of the IR absorption band
at 1205 cm-1. The analysis was performed as discussed in the experimental section and by plotting
the concentration vs Intensity of AUC of the peak, it was determined that aspirin had a linear
correlation.

Figure 25 shows the calibration data of aspirin with different concentrations of standard aspirin
solution. The concentrations range from 3 mM to 33 mM with r2= 0.9922 of AUC of aspirin IR
peak vs. concentration in simulated gastric fluid (pH 1.2).

Figure 26 shows the calibration data of aspirin with different concentrations of standard aspirin
solution. The concentrations range from 3 mM to 33 mM with r2= 0.9979 of AUC of aspirin IR
peak vs. concentration in sodium acetate buffer (pH 4.5).

Figure 27 shows the calibration data of aspirin with different concentrations of standard aspirin
solution. The concentrations range from 3 mM to 33 mM with r2= 0.9926 of AUC of aspirin IR
peak vs. concentration in potassium phosphate buffer (pH 6.8).
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3.3.2 Calibration of salicylic acid
Based on the IR spectra obtained, salicylic acid has an IR frequency of interest at 1488 cm-1 (for
simulated gastric fluid study) and 1388 cm-1 (for duodenum and intestine study). Linear regression
for salicylic acid was calculated by using the area under curve calculations of the IR absorption
band at 1388 and 1488 cm-1. The analysis was performed as discussed in the experimental section
and by plotting the concentration vs intensity of AUC of the peak, it was determined that salicylic
acid had a linear correlation.

Figure 28 shows the calibration data of salicylic acid with different concentrations of standards
with concentrations range from 3 mM to 33 mM with r2= 0.9908 of AUC of aspirin IR peak vs.
concentration in simulated gastric fluid pH (1.2).

Figure 29 shows the calibration data of salicylic acid with different concentrations of standards
concentrations from 3 mM to 33 mM with r2= 0.9961 of AUC of aspirin IR peak vs. concentration
in sodium acetate buffer (pH 4.5).

Figure 30 shows the calibration data of salicylic acid with different concentrations of standards
concentrations from 3 mM to 33 mM with r2= 0.9954 of AUC of aspirin IR peak vs. concentration
in potassium phosphate buffer (pH 6.8).
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Figure 25: Calibration graph of aspirin in simulated gastric fluid (pH 1.2)
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Figure 26: Calibration of aspirin in sodium acetate buffer (pH 4.5)
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Figure 27: Calibration of aspirin in potassium phosphate buffer (pH 6.8)
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Figure 28: Calibration graph of salicylic acid in simulated gastric fluid (pH 1.2)

73

30

0.35

Intensity of AUC

0.30
0.25
0.20
y = 0.0092x + 0.0231
R² = 0.9961

0.15
0.10
0.05
0.00
5

10

15

20

25

30

Concentration [mM]

Figure 29: Calibration graph of salicylic acid sodium acetate buffer (pH 4.5)
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Figure 30: Calibration graph of salicylic acid potassium phosphate buffer (pH 6.8) in [mM]
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3.3.3 Hydrolysis of aspirin to salicylic acid in test tube
A qualitative measurement was investigated to determine the presence of salicylic acid in solution.
This was carried out for the confirmation of the hydrolysis of the aspirin. Figure 31 shows that
after adding ferric chloride solution at 0 min, a purple color has formed immediately in a vial
containing salicylic acid (Vial-S), due to the formation of the iron-phenol complex. A sample of
pure aspirin (vial-A) should not exhibit any color change at time 0 min. Formation of iron phenol
complex gives definite color ranging from red to violet, depending on the amount of salicylic acid
present and pH of the buffer solution. After 60 min aspirin (vial A) showed a color change from
colorless to violet indicates that formation of salicylic acid after hydrolysis. The same test was
performed after the dissolution of aspirin tablet in simulated gastric fluid. The color of the
dissolution solution was changed from clear to purple after adding few drops of ferric chloride
solution, which confirmed the hydrolysis of aspirin to salicylic acid.
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Figure 31: Ferric chloride color test on standard solutions and on samples in the flask.
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3.3.4 Dissolution and hydrolysis of aspirin tablet in simulated gastric
fluid pH 1.2
This study was focused on performing dissolution, simultaneously observing hydrolysis of aspirin
by in-situ FT-IR in simulated gastric fluid. Figure 32 shows the dissolution and hydrolysis of
aspirin and formation of salicylic acid with time. The dissolution profile was monitored by in-situ
FT-IR and confirmed by HPLC analysis. The graph for both methods showed overlapping data
which gives the authentication of the in-situ FT-IR method. The graph has two lines, a brown line
depicts the dissolution of aspirin and a blue line depicts the formation of salicylic acid. A brown
line with steep upward trend indicates dissolution of aspirin in first 20 mins followed by downward
trend indicating hydrolysis of aspirin after 20 min. The blue line indicates the formation of salicylic
acid during this process. At initial stage of dissolution, small amount of salicylic acid was detected.
This might be because of the salicylic acid produced by aspirin in the process of manufacturing or
hydrolysis of aspirin can occurred upon storage. It is observed that the rate of dissolution is faster
at pH 1.2 compared to other pHs. The rate of dissolution is 1.706 mM/min in simulated gastric
fluid. Almost 90% of the aspirin was dissolved in first 15-20 min in simulated gastric fluid pH 1.2,
which indicates that stomach is the best place for the dissolution of the aspirin tablet. It was
observed that the rate of the dissolution rate of hydrolysis also faster than other pHs.
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After the dissolution and hydrolysis study was confirmed, a replicate study with the same
experimental conditions was performed as shown in Figure 33. During the replicate study, the
result of dissolution and hydrolysis of aspirin and formation of salicylic acid overlapped with the
initial study which confirmed the method.

Figure 34 shows the combined study of all dissolutions and hydrolysis of aspirin from all the
experiments. Data from all these experiments were combined to calculate standard deviation,
which is shown in the form of error bars within the range of 4-5%.

Table 2 shows the amount of aspirin and salicylic acid by in-situ FT-IR and HPLC methods. In
this table, the quantities are mentioned in the mM concentration instead of percent dissolution. The
Bayer aspirin tablet contains 325 mg of aspirin, was converted into millimolar concentration of
18.03 mM. The percent dissolution and hydrolysis of aspirin and formation of salicylic acid was
also converted to mM.
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Figure 32: Dissolution and hydrolysis of data in simulated gastric fluid (pH 1.2): in-situ FTIR vs. HPLC
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Figure 33: Dissolution and hydrolysis of data in simulated gastric fluid (pH 1.2): in-situ FTIR, Overlay
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Figure 34: Dissolution and hydrolysis of data in simulated gastric fluid (pH 1.2): in-situ FTIR, Combined study
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Table 2: Dissolution and hydrolysis data of aspirin tablet in simulated gastric fluid
Time in
mins
0
2
4
6
8
10
12
14
18
26
30
40
50
60
70
80
90

Salicylic
Acid by IR
[mM]
0.0
0.3
0.5
0.9
1.0
1.2
1.5
2.1
4.7
9.2
10.1
12.6
13.6
14.5
15.5
17.2
17.7

Aspirin
by IR
[mM]
0.0
1.1
3.1
8.1
12.9
14.9
17.6
15.8
13.1
8.7
7.6
5.3
4.4
3.4
2.2
0.7
0.3
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Salicylic
Acid by
HPLC [mM]
0.0
0.2
0.4
0.9
1.2
1.5
1.7
2.0
4.5
8.8
10.5
13.0
14.1
15.0
16.1
17.6
17.9

Aspirin by
HPLC
[mM]
0.0
0.9
3.5
7.6
13.5
15.6
17.8
15.9
13.5
9.1
7.1
5.1
3.8
3.2
1.5
0.3
0.2

3.3.5 Dissolution and hydrolysis of aspirin tablet in sodium acetate
buffer pH 4.5
In the method development of dissolution, it is a good practice to perform the dissolutions in
different body pHs and study the dissolution pattern. After gastric simulated fluid tablet moves to
the duodenum, another place where a tablet can dissolve in the body. This set of experiments
performed dissolution and simultaneously observed hydrolysis of aspirin by in-situ FT-IR in
sodium acetate buffer having pH 4.5 depicts duodenum pH and compared with HPLC.

Figure 35 shows the dissolution and hydrolysis of aspirin and formation of salicylic acid with time.
The dissolution profile was monitored by in-situ FT-IR and confirmed by HPLC analysis. The
graph for both methods showed overlapping data which gives the authentication of the in-situ FTIR method. The graph has two lines, a brown line depicts the dissolution of aspirin and a blue line
depicts the formation of salicylic acid. A brown line with steep upward trend indicates dissolution
of aspirin in first 3-4 hrs followed by downward trend indicating hydrolysis of aspirin after 3-4
hrs. The blue line indicates the formation of salicylic acid during this process. Thus the dissolution
and the hydrolysis of aspirin and at the same time formation of the salicylic acid was observed. At
initial stage of dissolution, small amount of salicylic acid was detected. This might be because of
the salicylic acid produced by aspirin in the process of manufacturing or hydrolysis of aspirin can
occurred upon storage. It was observed that the rate of dissolution is slower in pH 4.5 sodium
acetate buffer compared to simulated gastric fluid pH 1.2. The rate is affected on the basis of
acidity of dissolution medium that is 0.545 mM/min. The dissolution and hydrolysis of aspirin
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with the comparison of HPLC data and confirmed by this method. It was observed that the rate of
the dissolution rate of hydrolysis was slower than simulated gastric fluid pH 1.2.

After the dissolution and hydrolysis study was confirmed, a replicate study with the same
experimental conditions was performed as shown in Figure 36. During the replicate study, the
result of dissolution and hydrolysis of aspirin and formation of salicylic acid are overlapped with
the initial study which confirmed the method.

Figure 37 shows the combined study of all dissolutions and hydrolysis of aspirin from all the
experiments. Data from all these experiments were combined to calculate standard deviation,
which is shown in the form of error bars within the range of 3-4%.

Table 3 shows the amount of aspirin and salicylic acid by in-situ FT-IR and HPLC methods. In
this table, the quantities are mentioned in the mM concentration instead of percent dissolution. The
Bayer aspirin tablet contains 325 mg of aspirin, was converted into millimolar concentration of
18.03 mM. The percent dissolution and hydrolysis of aspirin and formation of salicylic acid was
also converted to mM
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Figure 35: Dissolution and hydrolysis of data in sodium acetate buffer (pH 4.5): in-situ FTIR vs. HPLC
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Figure 36: Dissolution and hydrolysis of data in sodium acetate buffer (pH 4.5): in-situ FTIR, overlay
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Figure 37: Dissolution and hydrolysis of data in sodium acetate buffer (pH 4.5): in-situ FTIR, combined study
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Table 3: Dissolution and hydrolysis data of aspirin tablet in sodium acetate buffer

Time
in hrs.
0
0.08
0.16
0.33
0.50
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Salicylic
Acid by
IR [mM]
0.0
0.3
0.5
0.9
1.1
1.3
2.1
2.3
2.5
2.4
3.2
4.2
5.5
6.2
8.0
10.3
11.6
13.0
14.5
14.9
15.0
15.4
15.7
15.8
16.0
16.3
16.5
16.7
17.1

Aspirin
Salicylic
by IR
Acid by
[mM] HPLC [mM]
0.0
0.0
3.0
0.4
5.9
8.1
12.1
1.6
14.5
1.9
15.3
2.3
16.1
2.4
17.6
2.5
16.0
2.4
14.9
2.9
13.7
4.4
12.5
5.8
11.7
7.1
9.9
9.4
7.4
11.2
6.3
5.1
3.4
3.1
2.9
2.7
2.2
2.0
1.9
1.8
1.4
16.3
1.3
16.5
1.2
16.9
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Aspirin by
HPLC
[mM]
0.0
4.3
11.5
13.7
15.9
16.9
17.7
16.4
15.2
13.6
12.1
10.9
8.4
6.7
1.8
1.3
1.2

3.3.6 Dissolution and hydrolysis of aspirin tablet in potassium phosphate
buffer pH 6.8
As per the physiological conditions, finally tablet reaches to the small intestine another place for
dissolution of pharmaceutical dosage forms. In this set of experiments were performed dissolution
and simultaneously observed hydrolysis of aspirin by in-situ FT-IR in phosphate buffer having pH
6.8 depicts small intestine pH and compared with HPLC.

Figure 38 shows the dissolution and hydrolysis of aspirin and formation of salicylic acid with time.
The dissolution profile was monitored by in-situ FT-IR and confirmed by HPLC analysis. The
graph for both methods showed overlapping data which gives the authentication of the in-situ FTIR method. The graph has two lines, a brown line depicts the dissolution of aspirin and a blue line
depicts the formation of salicylic acid. A brown line with steep upward trend indicates dissolution
of aspirin in first 7-8 hrs followed by downward trend indicating hydrolysis of aspirin after 7-8
hrs. The blue line indicates the formation of salicylic acid during this process. Thus the dissolution
and the hydrolysis of aspirin and at the same time formation of the salicylic acid was observed. At
initial stage of dissolution, small amount of salicylic acid was detected. This might be because of
the salicylic acid produced by aspirin in the process of manufacturing or hydrolysis of aspirin can
occurred upon storage. It was observed that the rate of dissolution is slowest in potassium
phosphate buffer pH 6.8 compared to other two pHs is 0.085mM/min. The dissolution and
hydrolysis of aspirin with the comparison of HPLC data and confirmed by this method. It was
observed that the rate of dissolution and hydrolysis was slowest than other pHs.
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After the dissolution and hydrolysis study was confirmed, replicate study with the same
experimental conditions were performed as shown in Figure 39. During the replicate study, the
result of dissolution and hydrolysis of aspirin and formation of salicylic acid overlapped with the
initial study which confirmed the method.

Figure 40 shows the combined study of all dissolutions and hydrolysis of aspirin from all the
experiments. Data from all these experiments were combined to calculate standard deviation,
which is shown in the form of error bars within the range of 3-4%.

Table 4 shows the amount of aspirin and salicylic acid by in-situ FT-IR and HPLC methods. In
this table the quantities are mentioned in the mM concentration instead of percent dissolution. The
Bayer aspirin tablet contains 325 mg of aspirin, was converted into millimolar concentration of
18.03 mM. The percent dissolution and hydrolysis of aspirin and formation of salicylic acid was
also converted to mM
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Figure 38: Dissolution and hydrolysis of data in potassium phosphate buffer (pH 6.8): insitu FT-IR vs. HPLC
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Figure 39: Dissolution and hydrolysis of data in potassium phosphate buffer (pH 6.8): in situ,
overlay
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Figure 40: Dissolution and hydrolysis of data in potassium phosphate buffer (pH 6.8): insitu FT-IR, combined study
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Table 4: Dissolution and hydrolysis data of aspirin tablet in potassium phosphate buffer
(pH 6.8)

Time
in hrs.
0
0.08
0.16
0.33
0.50
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Salicylic
Acid by
IR [mM]
0.0
0.2
0.4
0.5
0.6
0.8
1.1
1.6
1.8
2.0
2.1
2.3
2.4
2.5
2.7
3.3
3.9
4.8
6.0
6.8
7.5
8.0
9.0
10.6
11.4
12.2
12.9
13.6

Aspirin
by IR
[mM]
0.0
1.8
3.6
4.9
5.9
7.0
9.4
11.1
12.9
14.2
16.1
16.9
17.1
16.0
15.3
14.7
14.3
13.2
12.2
11.0
10.6
9.9
9.0
7.3
6.3
5.7
4.9
4.3

Salicylic
Acid by
HPLC [mM]
0.0
0.2
0.4
0.5
0.7
0.9
1.3
1.5
1.9
2.0
2.1
2.3
2.4
2.3
2.2
12.7
13.4

Aspirin
by HPLC
[mM]
0.0
1.6
4.0
5.2
6.2
7.3
9.5
10.7
12.5
13.9
15.6
17.0
16.1
15.7
15.3
5.5
4.6

24

14.3

3.8

14.7

3.4
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3.3.7 Kinetic study
The kinetic rates were also determined for the experiments discussed earlier. The kinetics of the
dissolution and hydrolysis is based on the concentration of aspirin, so it is a first order reaction.
[96] Kinetic study was determined by using the slope of the line and by using following formula
to study rate of dissolution and rate of hydrolysis.
ln[𝐴] = −𝑘𝑡 + ln[𝐴]0

(10)

The rates are compared to literature research [97] [98] [99]and were found dissolution rate to be
equivalent. The literature data shows the rate of hydrolysis of aspirin has a specific pH rate profile.
[100] The experimental values showed comparable rate profile. In this study, the rate of hydrolysis
of aspirin after dissolution is completely depends on the rate of dissolution. The main goal of this
is to monitor dissolution and hydrolysis of aspirin tablet. For the hydrolysis reaction, there must
be free aspirin present in the solution, which will be available after the dissolution of the tablet. So
as the rate of dissolution is slow with a change in the pH, hydrolysis is also slow.
The rates of the reactions were determined from the dissolution plots. In order to calculate the rates
using the plot, the following procedure was implemented. First, a plot log of percent dissolved vs.
time is obtained which was shown in the initial part of result section. Next, a straight line is drawn
over the area of the dissolution curve where dissolution starts to occur (middle area in this case).
Furthermore, the rate of hydrolysis is also calculated with the same method using the graph where
the hydrolysis starts, showed in the hydrolysis that is disappearance curve.
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Table 5 shows the rates of the dissolution and hydrolysis of aspirin in simulated gastric fluid pH
1.2. The rate was calculated using the equation 10. The table shows the rate of dissolution and
hydrolysis by both methods by calculation and the slope of the line. Rates of all the experiments
are shown in the table with an average of all data with standard deviation. The rate of dissolution
is 1.706 which is higher than the other buffer solutions. In this study, the rate of hydrolysis is
totally based on the rate of the dissolution, as the hydrolysis needs the free aspirin which generates
after dissolution.

Table 6 shows the rates of the dissolution and hydrolysis of aspirin in sodium acetate buffer pH
4.5. The table shows the rate of dissolution and hydrolysis by both methods by calculation and the
slope of the line. Rates of all the experiments are shown in the table with an average of all data
with standard deviation. The rate of dissolution and rate of hydrolysis slowed compare to simulated
gastric fluid is 0.545. As the dissolution slows the rate of hydrolysis is also slow.

Table 7 shows the rates of the dissolution and hydrolysis of aspirin in potassium phosphate buffer
pH 5.8. The table shows the rate of dissolution and hydrolysis by both methods by calculation and
the slope of the line. Rates of all the experiments are shown in the table with an average of all data
with standard deviation. The rate of dissolution and rate of hydrolysis slowest compare to other
two buffers is 0.085. As the dissolution slowest, the rate of hydrolysis is also slowest in this buffer.
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Table 5: Rate of dissolution and hydrolysis in simulated gastric fluid (pH 1.2)

By Calculations

By Slope

Rate of Dissolution

Rate of Hydrolysis

Rate of Dissolution

Rate of Hydrolysis

Exp

(mM/min)

(mM/min)

(mM/min)

(mM/min)

1

1.500

0.675

1.283

0.586

2

1.766

0.775

1.415

0.454

3

1.733

0.650

1.387

0.465

4

1.866

0.275

1.322

0.586

5

1.667

0.675

1.283

0.586

Avg

1.706

0.610

1.338

0.535

S. dev

0.136

0.193

0.061

0.069
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Table 6: Rate of dissolution and hydrolysis in sodium acetate buffer (pH 4.5)

By Calculations

By Slope

Rate of Dissolution

Rate of Hydrolysis

Rate of Dissolution

Rate of Hydrolysis

Exp

(mM/min)

(mM/min)

(mM/min)

(mM/min)

1

0.540

0.033

0.561

0.024

2

0.580

0.018

0.559

0.024

3

0.480

0.022

0.561

0.023

4

0.580

0.020

0.559

0.022

Avg

0.545

0.023

0.560

0.023

S. dev

0.047

0.007

0.002

0.001
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Table 7: Rate of dissolution and hydrolysis study in potassium phosphate buffer (pH 6.8)

By Calculations

By Slope

Rate of Dissolution

Rate of Hydrolysis

Rate of Dissolution

Rate of Hydrolysis

Exp

(mM/min)

(mM/min)

(mM/min)

(mM/min)

1

0.110

0.012

0.306

0.015

2

0.100

0.010

0.339

0.015

3

0.040

0.010

0.357

0.014

4

0.090

0.018

0.341

0.015

Avg

0.085

0.013

0.336

0.015

S. dev

0.031

0.004

0.022

0.000

100

3.4

Conclusion

The USP monograph of dissolution of aspirin explains about the conventional methods that are
UV/Vis and HPLC analysis, but the importance of this study is to perform the dissolution by FTIR in real time. The in-situ FT-IR measures the vibrations of a molecule in the fingerprint region,
which is important for the analyst, because each molecule has its own specific spectrum. Aspirin
has the tendency to hydrolyze and to form salicylic acid and acetic acid when it dissolves. So the
advantage of the in-situ FT-IR is to monitor dissolution as well as the hydrolysis of aspirin, which
is very difficult by UV/Vis and HPLC, because of the overlapping of these two peaks.
When the aspirin tablet was dropped into the dissolution medium, it starts to dissolve and slowly
hydrolyze into salicylic acid and acetic acid. The dissolution was performed on three different
body pHs and compared with HPLC. The results of the dissolution and hydrolysis study by both
methods are comparable, and this gives the validation of the new in-situ FT-IR technique. The
dissolution and hydrolysis of aspirin was monitored, in which two trends of the data was observed.
First trend explains about the dissolution of aspirin and followed by hydrolysis, so intensity if the
peak decreases gradually. The second trend is the formation of salicylic acid where the gradual
increase in the peak intensity was observed, based on the rate of hydrolysis. The rate of hydrolysis
and rate of formation of salicylic acid is based on the dissolution of the tablet. Once the tablet
dissolves, then the free aspirin will be available for the hydrolysis and as hydrolysis proceeds
formation of salicylic acid. So the rate of the reaction depends on the concentration as well as the
dissolution. This research was possible because of the versatility of the in-situ FT-IR system.
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This study demonstrated that in situ infrared spectroscopy is a viable technique for detecting and
measuring the hydrolysis of aspirin at different body pH. The in-situ FT-IR system was found to
be impressive in its capability of measuring low concentrations and was able to distinguish
separate components of a multiple component hydrolysis systems without requiring manual
sampling.

This versatility is demonstrated by observing the simultaneous dissolution and then elimination of
the acetylsalicylic acid component while monitoring the formation of the salicylic acid component
as acetylsalicylic acid undergoes hydrolysis. Specifically, the unique fingerprint region of the IR
spectra gave detailed information about the release profile of the drug. Conventional methods
would only show the release profile of one component. Moreover, the hydrolysis and
transformation of the drug from one form to another is missed with conventional techniques.
However, in-situ FT-IR captures those minor details and displays them in the fingerprint region,
as shown earlier. Furthermore, since this chapter successfully demonstrates the versatility of this
novel application of in-situ FT-IR spectroscopy, it suggests that the method has excellent potential
for the study of the dissolution and hydrolysis kinetics of pro-drug formulations.
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CHAPTER – 4
HYDROLYSIS STUDY OF ASPIRIN
4.1

Introduction

This chapter focuses on performing the dissolution and hydrolysis of different generic brands of
over the counter aspirin tablets with brand Bayer aspirin tablet by in situ FT-IR. As discussed
earlier aspirin undergoes hydrolysis to form salicylic acid and acetic acid. To perform dissolution
and hydrolysis of the different generic aspirin tablets were bought from Rite-Aid, Walgreen, CVS
pharmacies and Bayer aspirin with two different lot numbers. Two different brands of enteric
coated aspirin tablets are bought from India. The enteric coating prevents the dissolution of tablet
in acidic medium such as stomach and duodenum, tablet should dissolve in small intestine and
slowly release drug from pharmaceutical dosage form.
The comparison study of dissolution helps in the drug development of pharmaceutical dosage
forms. Fawzia and his group performed the comparison study of in vitro dissolution testing for
commercial available aspirin tablets, they observed similar dissolution profile for all brands of
aspirin. [101] Literature showed that comparison study of the dissolution with different brands has
been carried out. [102] Author compared the dissolution study with 23 generic tablets of
Levofloxacin with one branded tablet in Japan. Another study was on the design of the sustained
release tablets with different polymers and theirs quality control test to check the polymer effect
on the quality. [103] Clement and his group have compared the dissolution profile of 7 immediaterelease metformin 500 mg tablets. This study compared other characteristics such as weight
variation and drug content. The dissolution was carried on USP-II and they observed only one
formulation showed <85 % drug release in 15 min. [104] Issa and group have performed the
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comparative study of chlorpheniramine maleate orally disintegrating tablets. They have prepared
the different formulations by using different diluents and different disintegrating agents by direct
compression method. The formulation contains glucose crospovidone showed faster dissolution
as it disintegrates at faster rate compare to other formulations. [105] Ozkan and his group have
performed the comparison of dissolution on different designed and formulated salbutamol tablets.
This study was carried out using USP-I and USP-II. They observed the commercial formulation
showed the faster release of salbutamol. [106]
Literature study explains about the importance of the comparison study of dissolution and
developed motivation for this study. Thus interest has created to perform the dissolution of
different generic brands of aspirin tablets and compare with Bayer aspirin tablet. The different
generic brands of aspirin tablets were compared with Bayer aspirin tablet with same strength by
using in-situ FT-IR spectroscopy. The comparison of Bayer aspirin has performed with the enteric
coated tablets as well. The enteric coated tablets has a coating so that these tablets could not
dissolve in the stomach and duodenum.

4.2

Experimental Section

4.2.1 Chemicals and materials
Acetylsalicylic acid (aspirin) reference material (batch no. 016K0131) was purchased from SigmaAldrich. Salicylic acid reference material (batch no. 04708HE) was purchased from SigmaAldrich. Acetylsalicylic acid 325 mg tablets (Genuine Bayer batch no. 219050N) were purchased
from a local pharmacy. Another acetylsalicylic acid 325 mg tablets (Genuine Bayer batch no.
NAA01N9), Rite-Aid Pain relief Aspirin 325 mg tablets (batch no. 4125), CVS Genuine Aspirin
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325 mg tablets (batch no. 4200), Walgreen Regular strength Aspirin 325 mg tablets (batch
no.4148) and Bayer Advanced aspirin 500 mg tablets (batch no. 231051E) were purchased from
local Pharmacy store. Ecosprin 150 mg (batch no. 04005074) and Delisprin 150 mg (batch no.
M109M032) tablets were purchased from a local pharmacy from India. Methanol, acetone and
acetonitrile (HPLC grades) were purchased from Pharmaco-Aaper (Brookfield, CT). Sodium
chloride crystals (batch no. J39602) was purchased from Mallinckrodt Chemicals (England, UK).
Hydrochloric acid (batch no. H44032) was purchased from J.T. Baker (Central Valley, PA).
Sodium acetate crystals (batch no.05816HD, potassium phosphate monobasic (batch no.
103K0060) and sodium hydroxide (batch no. 06414BH) were purchased from Sigma-Aldrich
Chemicals (St. Louis, MO). Glacial acetic acid (batch no. 971666) was purchased from Fisher
Chemicals (Waltham, MA). All solutions were prepared using water treated by a Milli-Q plus
Millipore purification system (Milford, MA). All purified water aliquots have resistivity of not
less than 18 MOhm-cm-1.

4.2.2 Instrumentation
All chemicals were weighed on a Mettler Toledo balance (Washington Crossing, PA) PB303
Delta-Range® and AG204 Delta-Range®. The pH of the buffer was measured on a VWR
SympHony (Radnor, PA) SB70P pH meter. Dissolutions were carried out on the Easy MaxTM 102
by Mettler Toledo. HPLC analysis was performed on a Hewlett-Packard 1050 HPLC, with Chem
Station software. In-situ FT-IR analysis was carried on a Mettler Toledo iC 10 ReactIR, with iCIR
versions 3.0 and 4.0 software.
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4.2.3 Simulated gastric fluid
Simulated gastric fluid was prepared with hydrochloric acid and sodium chloride as per USP
procedure for buffers. 2 g of sodium chloride was dissolved in 100 mL of deionized amount of
water, in that 7 mL HCl was added and then volume made up to 1000 mL by adding deionized
water, and then measured pH of that solution and adjusted to 1.2.

4.2.4 Sodium acetate buffer
Sodium acetate buffer was prepared with glacial acetic acid and sodium acetate anhydrous as per
the USP procedures for buffers. 2.99 g of sodium acetate was dissolved in 100 mL of deionized of
water, in that 1.66 mL glacial acetic acid was added and then volume made up to1000 mL by
adding deionized water and then measured pH of that solution and adjusted to 4.5.

4.2.5 Potassium phosphate buffer
Potassium phosphate buffer (0.2 M) was prepared with monobasic potassium phosphate and
sodium hydroxide as per the USP buffer procedures. First potassium phosphate solution was
prepared by weighing 27.22 g of monobasic potassium phosphate and dissolved in 100 mL of
deionized water and diluted with up to 1000 mL. Next sodium hydroxide solution was prepared
by weighing 8 g of sodium hydroxide dissolved in water and made volume up to 100 mL. For
phosphate buffer added 50 mL of monobasic potassium phosphate solution in a 200 mL volumetric
flask then added 22.4 mL of sodium hydroxide solution and then added water to make a volume.
Finally measured the pH of this solution and was adjusted to 6.8.
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4.2.6 Standard solutions
For standard solutions weighed 325 mg of aspirin and salicylic acid and dissolved in 100 mL of
simulated gastric fluid, sodium acetate buffer and potassium phosphate and made concentration
3.25 mg/mL.

4.2.7 Dissolution and hydrolysis of all brands of aspirin tablets
All aspirin tablets were measured in pH 1.2 simulated gastric fluid solutions for 1.5 hr., pH 4.5
sodium acetate buffer for 24 hr and potassium phosphate buffer for 24 hr. Dissolutions were
conducted using vessel volumes of 100 mL and at 37.0 °C. All dissolutions were conducted using
USP Apparatus Type II (paddles) with an agitation speed of 100 rpm as per USP specifications.

4.2.8 In-situ FT-IR analysis
The set for dissolution testing was carried out as discussed in the experiment section. The in-situ
FT-IR fiber optic probe has collected baseline spectra (blank medium) for the first 30 minutes. A
single 325 mg Bayer aspirin tablet was dropped into the vessel containing 100 mL of buffer
solution (simulated gastric fluid pH 1.2, sodium acetate buffer pH 4.5 and potassium phosphate
buffer pH 6.8) and the dissolution profiles were collected using in-situ FT-IR spectroscopy.
Standard spectra of pure aspirin and salicylic acid were collected prior to running the dissolutions.
These standards were used to identify the unique peaks of interests for these active drugs. For the
aspirin tablet analysis, the same steps as discussed in calibration analysis were followed. The data
processing was carried out as mentioned in the previous chapter
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4.3

Results and Discussion

This study was focused to perform dissolution and simultaneously observation of hydrolysis of
different generic brands of aspirin with Bayer aspirin tablet by in-situ FT-IR in simulated gastric
fluid pH 1.2, sodium acetate buffer pH 4.5 and phosphate buffer pH 5.8.

4.3.1 Comparison between Bayer aspirin and Bayer advanced aspirin
tablets
Two separate dissolutionss were conducted by the procedure as mentioned in experimental section
on Bayer aspirin and Bayer Advanced aspirin tablet. This study was focused on performing
dissolution and simultaneously observe hydrolysis of aspirin by in-situ FT-IR in simulated gastric
fluid which depicts stomach environment having pH 1.2.
Figure 41 shows the dissolution profile of aspirin as per time with simultaneous hydrolysis of
aspirin and formation of salicylic acid of both the tablets. The dissolution profile was monitored
by in-situ FT-IR. The graph showed that the Bayer Advanced tablet showed the higher dissolution
than the Bayer aspirin tablet, as that tablet is immediate release tablet. In pH 1.2 gastric fluid the
rate of the dissolution is faster with Advanced Bayer aspirin tablet. Almost 90% dissolution of the
aspirin was observed in first 15-20 mins. which indicates that stomach is the best place for the
dissolution of the aspirin tablet. The Advanced Bayer aspirin tablet is an immediate release tablet
so it dissolves in the stomach at a high rate. The brown line in the graph represents Advanced
Bayer aspirin tablet and blue line represents Bayer aspirin tablet.
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Figure 41: Comparison of dissolution and hydrolysis of Bayer aspirin tablet and Bayer
advanced aspirin tablet by In-situ FT-IR in SGF
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4.3.2 Comparison between Bayer aspirin and generic aspirin tablets
This set of experiments performed dissolution and simultaneously observed hydrolysis of aspirin
by in-situ FT-IR in simulated gastric acid pH 1.2, sodium acetate buffer having pH 4.5 and
phosphate buffer pH 6.8 on Bayer aspirin tablets and other generic aspirin tablets. Each dissolution
was performed separately with same dissolution conditions and gone through the data treatment
on in-situ FT-IR.
Figure 42 shows the overlay plot of the dissolution profile of aspirin as per time, simultaneous
hydrolysis of aspirin and formation of salicylic acid in simulated gastric fluid pH 1.2. The plot
showed the dissolution and the hydrolysis data of 5 types of aspirin tablets which are mentioned
in the experimental section. All these tablets showed a similar trend for dissolution plot, then
aspirin peak intensity has decreased and at the same time formation of salicylic trend starts
increasing. The aspirin trend line has decreased shows the hydrolysis of aspirin. The dissolution
and hydrolysis all brands of aspirin tablets are similar to each other and they overlapped.
Figure 43 shows the overlay plot of the dissolution profile of aspirin as per time, simultaneous
hydrolysis of aspirin and formation of salicylic acid in sodium acetate buffer pH 4.5. The plot
showed the dissolution and the hydrolysis data of 5 types of aspirin tablets which are mentioned
in the experimental section. All these tablets showed a similar trend for dissolution plot, then
aspirin peak intensity has decreased and at the same time formation of salicylic trend starts
increasing. The aspirin trend line has decreased shows the hydrolysis of aspirin. The dissolution
and hydrolysis all brands of aspirin tablets are similar to each other and overlapped.
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Figure 42: Comparison of dissolution and hydrolysis of all brands of aspirin tablets by insitu FT-IR in simulated gastric fluid

111

16.0

Bayer Aspirin

New B SA

New B Aspirin

CVS SA

CVS Aspirin

Rite aid SA

Rite aid Aspirin

Walgreen SA

Walgreen Aspirin

20.0
18.0
16.0

14.0

14.0

12.0

12.0
10.0
10.0
8.0
8.0
6.0

6.0

4.0

Salicylic Acid Release [mM]

Dissolution and Hydrolysis of Aspirin [mM]

18.0

Bayer SA

4.0

2.0

2.0

0.0

0.0
0

2

4

6

8

10

12

14

16

18

20

22

24

26

Time in Hour

Figure 43: Comparison of dissolution and hydrolysis of all brands of aspirin tablets by insitu FT-IR in sodium acetate buffer
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Figure 44: Comparison of dissolution and hydrolysis of all brands of aspirin tablets by insitu FT-IR in phosphate buffer
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Figure 44 shows the overlay plot of the dissolution profile of aspirin as per time, simultaneous
hydrolysis of aspirin and formation of salicylic acid in potassium phosphate buffer pH 5.8. The
plot showed the dissolution and the hydrolysis data of 5 types of aspirin tablets which are
mentioned in the experimental section. All these tablets showed a similar trend for dissolution plot,
then aspirin peak intensity has decreased and at the same time formation of salicylic trend starts
increasing. The aspirin trend line has decreased shows the hydrolysis of aspirin. The dissolution
and hydrolysis all brands of aspirin tablets are similar to each other and overlapped on.

4.3.3 Dissolution of enteric-coated tablets
The next step of the comparison study of dissolution and hydrolysis of aspirin is to perform the
the dissolution of enteric coated aspirin tablets. The enteric coated means, that the tablet is coated
with a material to prevent the dissolution process in the stomach and in duodenum but allow
dissolution in the small intestine. The advantage of this coating is to avoid dissolution of those
compounds which creates stomach irritations. The Ecospirin-150 and Delisiprin-150 tablets were
selected for this study. The dissolution of these tablets was carried out in simulated gastric fluid
pH 1.2 and sodium acetate buffer pH 4.5 up to 24 hrs. for the confirmation of the enteric coating
and observed that both tablets showed no dissolution in both buffers. At the end of 24 hrs. tablets
were present in the dissolution media in its initial form. However, the dissolution of these tablets
were performed in phosphate buffer pH 6.8 and observed the dissolution of aspirin followed by
hydrolysis.
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The dissolution of Ecospirin-150 was carried as per the procedure mentioned in the experimental
section. Figure 45 shows the comparison of dissolution and hydrolysis data of aspirin. The similar
profile was observed as discussed earlier. The dissolution of aspirin plot was increased as per the
time and after dissolution, simultaneous hydrolysis of aspirin was observed. With this formation
of salicylic acid was also observed in potassium phosphate buffer pH 6.8.The dissolution was
compared with Bayer aspirin tablet. The data was overlapped.

The dissolution of Delisprin-150 was carried as per the procedure mentioned in the experimental
section. Figure 46 shows the comparison of dissolution and hydrolysis data of aspirin. The similar
profile was observed as discussed earlier. The dissolution of aspirin plot was increased as per the
time and after dissolution, simultaneous hydrolysis of aspirin was observed. With this formation
of salicylic acid was also observed in potassium phosphate buffer pH 6.8.The dissolution was
compared with Bayer aspirin tablet. The data was overlapped.
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Figure 45: Dissolution and hydrolysis of Ecospirin-150 tablet by in-situ compared with Bayer
aspirin in Phosphate buffer
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Figure 46: Dissolution and hydrolysis of Delisprin-150 tablet by in-situ FT-IR compared with
Bayer aspirin tablet in Phosphate buffer

117

4.3.4 Kinetic study
The kinetic study was determined by using the slope of the line and by using following formula
calculated the rate of dissolution and rate of hydrolysis.
ln[𝐴] = −𝑘𝑡 + ln[𝐴]0

(11)

The rates of the reactions were determined from the dissolution plots. In order to calculate the rates
using the plot, the following procedure was implemented. First, a plot log of percent dissolved vs.
time is obtained which was shown in the initial part of result section. Next, a straight line is drawn
over the area of the dissolution curve where dissolution starts to occur (middle area in this case).
Furthermore, the rate of hydrolysis is also calculated with the same method using the graph where
the hydrolysis starts, showed in the hydrolysis that is disappearance curve.
As the main goal is to study the dissolution of an aspirin tablet and with that monitoring hydrolysis
of aspirin. For the hydrolysis reaction, there must be free aspirin present in the solution, which will
come after the dissolution of the tablet. So as the rate of dissolution is slow with a change in the
pH, hydrolysis is also slow.
Table 8 shows the rate of dissolution and rate of hydrolysis of all dissolutions data. The list of
brands of aspirin tablets and their dissolution and hydrolysis rates has shown in the table. The
kinetic data is similar with Bayer aspirin tablet.
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Table 8: Kinetic data of all brands of aspirin tablets

Simulated Gastric Fluid

Sodium Acetate Buffer

Potassium Phosphate Buffer

Name of
Aspirin
Tablet

Rate of
Dissolution
(mM/min)

Rate of
Hydrolysis
(mM/min)

Rate of
Dissolution
(mM/min)

Rate of
Hydrolysis
(mM/min)

Rate of
Dissolution
(mM/min)

Rate of
Hydrolysis
(mM/min)

Bayer

1.706

0.610

0.545

0.023

0.085

0.013

New Bayer

1.679

0.723

0.523

0.028

0.100

0.017

Rite-Aid

1.721

0.654

0.567

0.030

0.088

0.012

Walgreens

1.680

0.741

0.601

0.021

0.110

0.015

CVS

1.694

0.634

0.569

0.024

0.094

0.013

Ecospirin

-

-

-

-

0.079

0.014

Delisprin

-

-

-

-

0.083

0.015
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4.4

Conclusion

The in-situ FT-IR records vibrations in the fingerprint region, which is important for the analyst,
because each molecule has its own specific spectrum. Aspirin has the tendency to hydrolyze and
to form salicylic acid and acetic acid when it dissolves. So the advantage of the in-situ FT-IR is to
monitor dissolution as well as the hydrolysis of aspirin, which is very difficult by UV/Vis and
HPLC, because of the overlapping of these two peaks. As the aspirin tablet dropped into the
dissolution medium, it starts to dissolve and slowly hydrolyzes into salicylic acid and acetic acid.
The dissolution was performed on three different body pHs and compared with HPLC in the
previous chapter and validated.
The dissolution and hydrolysis of Bayer aspirin tablets were monitored and compared with the
generic aspirin tablet and enteric coated aspirin tablet. The profile showed the two trends of the
data has been seen in all the tablets. The first trend explains about the dissolution of aspirin and
followed by hydrolysis so intensity if the peak decreases gradually. The second trend is the
formation of salicylic acid where the gradual increase in the peak intensity can has seen, based on
the rate of hydrolysis. The enteric coated tablets dissolution and hydrolysis has compared with
Bayer aspirin tablet. This research was possible because of the versatility of the in-situ FT-IR
system.
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CHAPTER - 5
DISSOLUTION OF LORATADINE
5.1 Introduction
In the previous sections, the versatility of in-situ FT-IR which is dissolution and hydrolysis study
of aspirin and dissolution of acetaminophen were discussed in detail. Another over-the-counter
antihistaminic drug, loratadine has been chosen for the further confirmation of the new in-situ
analysis technique to monitor dissolution. [107]
Loratadine is a second-generation antihistamine antagonist drug used to treat allergies. The FDA
approved Loratadine in 1993. Loratadine is effective for both nasal and eye symptoms: sneezing,
runny nose, and itchy or burning eyes. [108] Loratadine could be also used to treat mild to
moderate pain from headaches. The mechanism of action of loratadine is a tricyclic antihistamine
which acts as a selective inverse agonist of peripheral histamine H1-receptors. Histamine is
responsible for many features of allergic reactions. Loratadine is metabolized by cytochrome P450,
primarily by CYP3A4 and CYP2D6 isozymes. [109] Loratadine is a prodrug which hydrolyzes
into descarboethoxy loratadine also known as desloratadine. [110] [111]There are recent studies
of dissolution of loratadine and the formulation with different dosage forms by different drug
delivery system are found in the literature. [112]
Mondal and Islam have prepared loratadine formulations based on Self Emulsifying Drug Delivery
System (SEDDS). They used oleic acid and cremophore EL surfactant with different
concentrations and performed the dissolution study by using USP-II. They observed the rate of
drug release has increased with increased amount of cremophor EL surfactant in the formulation.
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[113] Borgaonkar and group have studied the dissolution of loratadine buccal tables to enhance
the bioavailability and to minimize the first pass metabolism, they prepared loratadine tablets using
different polymers. They finalized that the hydroxypropylmethylcellulose is good for the
dissolution study as they found 99% in-vitro drug release in 8 hr. with satisfactory mucoadhesion
strength. [114]
Soni and Sagar designed the quick dissolving loratadine tablets by compression method. The
dissolution of the formulation is used for the stability study. [115] Qadir and group have formulated
fast dissolving films of loratadine for sublingual use. They performed the dissolution of loratadine
films by USP-II with the observation that with increased content of PVP, the rate and extent of
drug release was faster. [116] Another study was carried out to enhance the solubility if loratadine
by using cyclodextrin binary system. [117]
The novelty of this study is to perform the dissolution by in-situ FT-IR, without manual sampling
and disturbing dissolution process. The dissolution data

5.2

Experimental Section

5.2.1 Chemicals and materials
Loratadine reference material used in this study is CAS # 79794-75-5. Claritin 10 mg tablets which
contains loratadine was purchased with (lot number 2RXF523) from a Rit-Aid pharmacy.
Methanol, acetone and acetonitrile (HPLC grades) were purchased from Pharmaco-Aaper
(Brookfield, CT). Hydrochloric acid (batch no. H44032) was purchased from J.T. Baker (Central
Valley, PA). Solutions were prepared using water treated by a Milli-Q Millipore purification
system (Milford, MA). All purified water aliquots have resistivity of not less than 18 MOhm-cm1

.
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5.2.2 Instrumentation
All chemicals were weighed on a Mettler Toledo balance (Washington Crossing, PA) PB303
Delta-Range® and AG204 Delta-Range®. The pH of the buffer was measured on a VWR
SympHony (Radnor, PA) SB70P pH meter. Dissolutions were carried out on the Easy MaxTM 102
by Mettler Toledo. In-situ FT-IR analysis was carried on a Mettler Toledo iC 10 ReactIR, with
iCIR versions 3.0 and 4.0 software.

5.2.3 0.1 N hydrochloric acid
0.1 N HCl was prepared as per the USP procedure for buffers. [118] 8.5 mL of concentrated HCl
was diluted with 1000 mL of deionized water for the analysis.

5.2.4 Loratadine solution for calibration
Loratadine stock solution of concentration 10 mg/mL was prepared by dissolving 500 mg of
loratadine in 50 mL of 0.1 N HCl. Nine dilutions were prepared by adding 1.00, 2.00, 3.00, 4.00,
5.00, 6.00, 7.00, 8.00 and 9.00 mL of this stock solution respectively to 10.00 mL volumetric flasks
respectively and diluting to volume with 0.1 N HCl for the calibration curve. The concentration of
loratadine in each flask was 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50 and 5.00 mg/mL
respectively. Loratadine has a tendency to hydrolyze as it goes into solution. Solutions were placed
into an ice bath immediately after the preparation to slow down the hydrolysis process. As soon as
solutions were ready, they were scanned by in-situ FT-IR for the calibration study at room
temperature.
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5.2.5 Standard solutions
The standard solutions of concentration 0.1 mg/mL was prepared using 10 mg of loratadine was
dissolved in 100 mL of 0.1 N HCl.

5.2.6 Dissolution of loratadine
Claritin tablet 10 mg of loratadine (label claim) were tested in pH 0.1N HCl solutions for 2 hr.
Dissolutions were conducted using vessel volumes of 100 mL and at 37.0 °C. All dissolutions
were conducted using USP-II (paddles) with an agitation speed of 50 rpm as per the USP
monograph of loratadine. [119]

5.2.7 In-situ FT-IR analysis
For the calibration of aspirin experiments, data treatment was carried out using the following
methodology: The data was first subjected to baseline correction. The absorption band at 1246
cm-1 (corresponding to the C-N stretch) was selected for loratadine as shown in Figure 47 with the
calibration study. [120] The figure is the overlay calibration data of the loratadine from the in-situ
FT-IR software in 0.1 N HCl. A distinct peak for loratadine without any interfering peak was
observed. The peak at 1246 cm-1 has increased intensity with increased concentration. The
different concentration of loratadine solution also ran three times and the spectra overlapped on
each other. The peak area was calculated using a two-point baseline correction set at 1265 cm-1
and 1230 cm-1. The in-situ FT-IR system was configured to collect spectra every two minutes at
room temperature.
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For this experiment, data processing is critical to obtain well-resolved spectra. Here is how the
data is processed. For all in-situ FT-IR experiments, 256 scans were collected and co-added for
each spectral point on average and each data point took about two minutes to complete. First, the
peak of interest was identified (1246 cm-1) and the area was calculated using a two-point baseline
correction. Next, a trend analysis was performed using the iCIR software on this peak. This
provided a plot of absorbance vs. time. This plot was subjected to smoothing using a 25 point
smoothing parameter. After smoothing, and while still in the trend analysis, the baseline correct
routine was performed. Then, the data were exported to Excel. Further data processing in Excel
involved the subtraction of solvent spectra from reaction spectra. To perform this, a 30 min set of
spectra at the beginning of the experiment, before claritin pill was added, was selected. These
spectra were subtracted from the spectra taken after the pill was dropped to give the final set of
data. Within the final set of data, the area of the 1246 cm-1 peak was calculated at each time point.
Then the plot of area vs. time was performed to give rate information. In addition, using a
calibration curve, peak areas were converted to concentration to provide concentration vs. time
plots.
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Figure 47: Loratadine in-situ FT-IR peak at 1246 cm-1 for calibration
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5.3

Results and Discussion

5.3.1 Calibration of loratadine
Based on the in-situ FT-IR spectra obtained, loratadine has an IR frequency of interest at 1246 cm1

. Based on the analysis, it was determined that loratadine had excellent linear correlation using IR

spectroscopy with a 0.9951 in 0.1 N HCl correlation coefficient (r2) and shown in Figure 48. Linear
regression for loratadine was calculated by using the area under curve calculations of the IR
absorption bands.

5.3.2. Dissolution of loratadine
The data was compared to reference standards measurements collected prior to the start of the
linearity and dissolution experiment. Dissolution data was plotted vs. time. Figure 49 shows the
dissolution profiles of loratadine by the in-situ FT-IR instrument software. Experiment and the
dissolution media was equilibrated for first 30 mins and then dropped the tablet in the dissolution
vessel. The dissolution performed for longer time to check the stagnant line after complete
dissolution. Figure 49 showed the dissolution profile of loratadine per time, within 15-20 min 50%
of loratadine dissolved. Once the dissolution study has confirmed, performed a replicate study with
the same experimental conditions.
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Conclusion

The dissolution loratadine was performed successfully by using in-situ FT-IR spectroscopy. The
calibration of the loratadine from 1 mg/mL to 5 mg/mL was carried out and showed liner
correlation with r2 value 0.9951. The dissolution was performed successfully, in first 40 mins more
than 80% of loratadine has dissolved. This study demonstrated and confirmed that in situ FT-IR is
a viable technique for monitoring the dissolution of the pharmaceutical dosage form. The in situ
FT-IR system was found to be impressive in its capability of measuring low concentrations without
requiring manual sampling.
This versatility has demonstrated by observing the simultaneous dissolution and then hydrolysis
of prodrug such as aspirin. Specifically, the unique fingerprint region of the IR spectra gave
detailed information about the release profile of the drug.
As future work of this study is to monitor the hydrolysis of loratadine as it is a prodrug. The active
metabolite of loratadine metabolism is after hydrolysis, which has more pharmacological potencies
than the parent drug. As per the conventional methods, it is very difficult to analyze these
components. By this technique, these two components can find distinct separate peaks for
loratadine and desloratadine as like the aspirin and salicylic acid. By this method, the dissolution
of loratadine can monitor with the transformation of loratadine to desloratadine which is difficult
in the conventional method.
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Research Summary
Dissolution studies are critical tests for measuring the performance of a drug product. In this
dissertation, a new technique, in-situ attenuated total reflection infrared spectroscopy (in-situ FTIR), has been developed to monitor dissolutions of pharmaceutical drug formulations. The
accuracy of this technique was determined to be relative to HPLC. Three over-the-counter (OTC)
active drugs (i.e., acetaminophen, acetylsalicylic acid and loratadine) were tested during the
research. Moreover, these drug formulations were tested and the individual components were
identified by in-situ FT-IR spectroscopy.
Very first project in this research is dissolution of acetaminophen, the potential of the in-situ FTIR spectroscopy for the quantitative analysis such as monitor the dissolution was observed. During
these experimentation, the non-linear Beer-Lambert’s behavior was observed, the hypothesis
behind this behavior was proposed due to the dimerization of the acetaminophen molecules. As
per the literature, for the confirmation of the dimerization studies were performed on the NMR,
FT-IR, Osmometry and freezing point depression. But, there was a lack of any evidence to confirm
the hypothesis of dimerization of acetaminophen.
Furthermore, the system has the capability of monitoring drug transformations during dissolution.
For instance, using this technique the hydrolysis of aspirin to salicylic acid was monitored.
Moreover, the simultaneous dissolution and elimination of aspirin has been monitored and at the
same time the formation of salicylic acid in solution has been monitored. The dissolution
monitored on the three different body pHs, that is stomach pH 1.2, duodenal pH 4.5 and last
intestinal pH 6.8 and the kinetics of the dissolution as well as hydrolysis were performed. However,
the stomach pH is the best dissolution media where the rate of dissolution and hydrolysis is fast.
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As the rate of hydrolysis is based on the dissolution of aspirin because it needs free aspirin in the
media, then aspirin transforms into salicylic acid, which observed slow in higher pHs as aspirin
dissolves slowly.
Dissolution and hydrolysis of aspirin study was performed using in-situ FT-IR spectroscopy and
compared with HPLC on Bayer aspirin tablet. In-situ FT-IR spectroscopy was compared with
different brands of generic aspirin tablets with the same strength. The rate of dissolution and
hydrolysis of all these brands are similar to Bayer aspirin. Dissolution of the enteric coated aspirin
tablet were performed, which dissolved in intestinal pH and used for the delayed release.
Loratadine was another pro-drug selected for the dissolution and hydrolysis study. This thesis
explains about the dissolution of loratadine and hydrolysis can be a study for future work.
The in-situ FT-IR system was found to have very good sensitivity for monitoring dissolution test.
The in-situ FT-IR has great potential for use in studies of dissolution of drugs and monitoring
competing for reactions such as hydrolysis of prodrugs in pharmaceutical development,
formulation and quality assurance without disturbing dissolution system as well as manual
sampling.
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Appendix
Standard Operating Procedure for ReactIR
This chapter explains the detail and stepwise standard operating procedure.
Starting Instrument:
1. Verify whether the instrument is on or off. (Usually, instrument is kept on. Please do an
additional check).
2. Fill in the liquid nitrogen through the funnel shown in Figure 50 and wait for 45 mins for
cooling the detector. To filling the liquid nitrogen, remove the nozzle and fit in the funnel,
then pour the liquid nitrogen with the help of the liquid nitrogen container in the funnel.
Stop pouring the liquid nitrogen in the funnel, after it starts overflowing.
3. Turn on the computer.

Remove nozzle to fill
the liquid nitrogen

Figure 50: ReactIR nozzle for liquid nitrogen
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Funnel to fill
liquid nitrogen

Figure 51: ReactIR nozzle with funnel

Starting Software:
1. The ReactIR uses iC IR 4.0 for analysis. On the desktop, the iC IR 4.0 icon is highlighted
with purple color. To start the software double-clicks the icon, which would bring up the
software window shown in Figure 52.

iC IR Software
4.0

Figure 52: Screenshot shows iC IR 4.0software icon
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Figure 53: Screenshot of start page of ReactIR software

2. On the left hand side, there is a button for the” new experiment” as shown in Figure 54. To
start the new experiment click that button, and a small wizard window as shown below
should pop up. To check previous experimental data, then “open experiment” button opens
completed experiments.

Click this Button

Figure 54: Experimental section of iC IR software
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Figure 55: Screenshot of iC IR software and configuration window

3. Before starting any experiment, it’s a good practice to configure instrument. To configure
the instrument, click the configure instrument button, which is located on the bottom left of
the new experiment window.
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For configuration of IR

Figure 56: Enlarge view of configuration window

Configuration of Instrument:
1. Once the “Configure instrument” button is selected, the following window below will
appear. The specific instrument parameters can be modified using this part of the software.
In most cases, the default settings, as shown in Figure 57, will be acceptable for the
dissolution experiments. However, in some instances, the settings may be modified. These
modified settings will be explained later in the document.
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Figure 57: Configure hardware and software setting
a. The very first point in this configuration window is the name or type of the instrument.
Here, ReactIR 10 is the default option for the instrument because this is the name of
the instrument. As shown in Figure 58, the next option is the detector. There are 2 kinds
of detector one is MCT (Mercuric Cadmium Telluride) and another one is DTGS
(deuterated triglycine sulfate). For this instrument, MCT detector is used because this
detector is more sensitive than the DTGS. Usually, these options are selected, but if
not, it can be modified manually by clicking the restore defaults button.

Figure 58: Detector settings
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b. The next part in this window is the “Probe Hardware settings”. Since the instrument
contains a 9.5 mm x 1.5 m silver halide probe with a covered diamond tip, the following
parameters need to be selected as shown in Figure 59. There are numerous probe
settings available in the system. These can be found by selecting the drop down arrow
as shown below. So that it creates the facility to change the probe.

Dropdown
Arrow

Figure 59: Probe hardware settings
c. This instrument software can allow other kinds of the probe as shown in Figure 26.
Once the probe has changed, it’s mandatory to change the probe hardware setting in
the configuration window, such as in probe interface K4 conduit and in probe tip
SiComp (Silicon) option by using the drop-down arrow as shown in Figure 60. These
three probes below can be used for this instrument and software also.

Figure 60: Different type of IR Probes
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Dropdown
Arrow

Figure 61: Probe hardware settings for different types of probe
d. The last step of configuring the instrument is “Probe acquisition settings”. Resolution
is the first option which is shown in Figure 62. There are three kinds of resolution
options.


Normal (every 8 wavenumbers) resolution, usually this option is the best option
for dissolution experiment.



High (every 4 wavenumbers) resolution, will slow down scan rate and
application processing. It may be useful in certain reactions to help resolve
overlapping peaks.



Low (every 16 wavenumbers), this choice is only useful in reactions with broad,
non-overlapped peaks that require a fast sampling rate.

For the wave number range, instrument can run from 1900 to 650 cm-1 is because of
the diamond probe tip. By using the dropdown arrow for the scans options, will change
the number of scans. By choosing an auto select option, the instrument will select 256
scans.
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Figure 62: Probe acquisition Settings

2. Once finished with all modifications in parameters for the configuration of the instrument,
it’s time to move to the next step. Click the “Next” button. The next window will appear
as shown in Figure 65, with the picture of the instrument and the probe. Click “Next” button
to move further.

Figure 63: Position of the probe
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3. The pop-up window as shown in Figure 64 seen on the screen, which explains about the
alignment of the probe. For the alignment of the probe, Peak Height should be more than
18,000 and less than 28,000 and Contrast should be more than 10.00. If peak height and
contrast is more than these mentioned values, the two bars will change into green. If peak
height and contrast is less than these values, the bars are in red color and length is also less
compare to green bars. Once the bars turns to green, then press the “Next” button.

Figure 64: Align probe window
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4. The window shown in Figure 65 is used to collect the background. Here is the option for
the scans, from the drop-down list, the values for the number of scans can be changed.
Then click the “Collect Background” button. To collect the background normally takes 12 min, but it also depends on the number of scans option. After collection of the background
click the “Next” button.

Figure 65: Collect background window
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5. Then “collect water vapor sample” window will open. This page of the wizard is used to
collect a reference spectrum of water vapor. This reference spectrum is used for subtracting
out water vapor from a data set. It is not intended to be a replacement for an effective dry
air or nitrogen purge. The water vapor reference spectrum is simply a convenient way to
remove small amounts of water vapor which may enter or leave the instrument over a long
reaction period. After collection of the water vapor click the “Finish” button for completion
of the configuration of the instrument.

For Collection

For completion of
Configuration

Figure 66: Collect water vapor sample window
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Starting New Experiment:
1. After completion of the configuration, the Figure 67 will appear on the screen. In the
“Experimental File” the first option is for the name of the experiment. The naming of the
experiment is dependence on the patron/performer. The “Experiment Folder” option gives
options of where the experiment will be saved. Click the “Next” button.

Figure 67: Name experiment file
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2. This window gives the choice to set the time for the experiment and give the interval time
for the scans. As per the mentioned experiment time and interval time, the software will
show the total number of samples. Then click the “Next” button for next step.

Figure 68: Experiment duration window
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3. This window is the “reference spectra needed”. There are 4 kinds of reference options that
are available in this window. Usually, the first option is selected, that option is for the
collections of the reference spectra. There are other three types of options, in which one is
for the previously collected reference spectra; the next one is for no spectra and the last
one is for the direct start of the experiment. Then click the “Next” button.

Figure 69: Reference spectra window
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4. The next window again will show the picture of the instrument and the probe. The picture
will appear as below. Then click the “Next” button.

Figure 70: Position of the probe
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5. The align probe window will appear as shown in Figure 64. The position of the probe and
mirror should be aligned and if it is aligned then the bars will turn into the green color.
Otherwise, it will remain red. Click the “Next” Button.
6. In the next window, which is for the cleaning of the probe, there are two bars, one is for
the purging and one is for cleaning the probe. If purging and cleaning are proper then these
bars are green as shown below. The deionized water is the best solvent, for the cleaning of
the probe, also use acetone and 0.2 N hydrochloric acid (very very dilute). So that all small
traces of the previous experiment will dissolve in these solvents and the probe will be clean.
Click the “Next” button.

Figure 71: Clean probe window
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7. The “collect background” window will open.The main purpose of this window is to collect
the air background. The number of scans option can be chosen from the drop-down arrow
list or the default option is 256 scans. Then click the “Collect Background” button. The
collection of the background normally takes 1-2 min, but it also depends on the number of
scan options. Once the background is collected, click the “Next” button.

To collect
background
For next Window

Figure 72: Collect background window
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8. In the sequence of collecting primary data, the next window is for the “collect sample”.
Collect sample means the collection of spectra from the reference material, such as solvent,
reagent or any other reference material which is needed for the experiment. The window
contains three kinds of options, the first option is for naming the reference. The second
option gives an idea about, which kind of reference (the options are given by the dropdown arrow). The last option is the functional group, which is present in the reference.
(This option is also chosen by using the drop-down arrow). Once all settings are completed,
insert the probe into a beaker which contains sample or reference, then click the “Collect
Sample” button. (The collect button is disabled in the picture below, but after the name of
the reference is written and the reference option is selected, the “Collect Sample” button
will be enabled). Then Click the “Next” button.

Figure 73: Collect reference window
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9. This window gives an idea of the names of all references which are already collected. There
are four different buttons at the bottom of this window.


View Button- used to study or to check the reference spectra. The spectra will open
in a new window with all references. All the names of reference spectra can be seen
in the empty space under the “Component” heading as shown in the picture below.



Delete Button- the delete button is used to delete a spectrum that is not of good
quality. For deleting the spectrum, first select the name of the spectrum, (this will
enable the delete button) then click the delete button.

Once finished click the “Next” button for the next step.

Figure 74: Edit reference window
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10. After collecting the reference spectra, the instrument will show the clean probe window
again as shown in Figure 71. It means that before starting the experiment, the probe should
be clean. Whatever traces from the reference material which is present on the probe must
be removed by cleaning. The clean probe window will appear as shown below. Once the
probe is cleaned two green bars will appear showed as below will appear on the screen.
Click the “Next” button.
11. In front of the screen should be a “Collection Background” window as shown in Figure 72.
The main importance of collecting background is, the instrument can start its new
experiment with a fresh setting for the better results and good quality of spectra. Then click
the “Finish” button which is at the bottom of this window. After this step all the preliminary
requirements are finished, it will open a new experiment window.
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